No retraction, correction or concern found when last checked on Oct 16, 2026.

Neurotrophic Factor BDNF, Physiological Functions and Therapeutic Potential in Depression, Neurodegeneration and Brain Cancer

Luca Colucci-D’Amato, Luisa Speranza, Floriana Volpicelli

International Journal of Molecular Sciences · 2020 · Review · CC BY

doi:10.3390/ijms21207777

Abstract

Brain-derived neurotrophic factor (BDNF) is one of the most distributed and extensively studied neurotrophins in the mammalian brain. BDNF signals through the tropomycin receptor kinase B (TrkB) and the low affinity p75 neurotrophin receptor (p75NTR). BDNF plays an important role in proper growth, development, and plasticity of glutamatergic and GABAergic synapses and through modulation of neuronal differentiation, it influences serotonergic and dopaminergic neurotransmission. BDNF acts as paracrine and autocrine factor, on both pre-synaptic and post-synaptic target sites. It is crucial in the transformation of synaptic activity into long-term synaptic memories. BDNF is considered an instructive mediator of functional and structural plasticity in the central nervous system (CNS), influencing dendritic spines and, at least in the hippocampus, the adult neurogenesis. Changes in the rate of adult neurogenesis and in spine density can influence several forms of learning and memory and can contribute to depression-like behaviors. The possible roles of BDNF in neuronal plasticity highlighted in this review focus on the effect of antidepressant therapies on BDNF-mediated plasticity. Moreover, we will review data that illustrate the role of BDNF as a potent protective factor that is able to confer protection against neurodegeneration, in particular in Alzheimer’s disease. Finally, we will give evidence of how the involvement of BDNF in the pathogenesis of brain glioblastoma has emerged, thus opening new avenues for the treatment of this deadly cancer.

Full text

From PubMed Central, U.S. National Library of Medicine, as current on Oct 16, 2026. Paragraph numbers are ours, so an answer can point at one.

1. Introduction

1The neurotrophin BDNF is one of the most studied and well characterized neurotrophic factors in the CNS. It regulates many different cellular processes involved in the development and maintenance of normal brain function by binding and activating the TrkB, a member of the larger family of Trk receptors. In the brain, BDNF is expressed by glutamatergic neurons, glial cells, such as astrocytes isolated from the cortex and hippocampus, but not from the striatum, and microglia. During embryogenesis, BDNF–TrkB signaling promotes the differentiation of cortical progenitor cells and later promotes differentiation of cortical progenitor cells into neurons (i.e., neurogenesis). Several lines of evidence also suggest that the BDNF/TrkB signaling is involved in adult neurogenesis in the hippocampus with differing effects in the dentate gyrus (DG) and subventricular zone (SVZ). Adult neurogenesis in the dentate gyrus is enhanced by voluntary exercise, exposure to an enriched environment, and chronic antidepressant administration. Recently, it has also been proposed that caloric restriction and intermittent fasting in particular, appears to positively modulate hippocampal neurogenesis and BDNF. The connection between BDNF and the modulation of hippocampal neurogenesis by external stimuli is a topic that has been extensively studied in recent years. It has been demonstrated that voluntary physical exercise, like an enriched environment, increases expression of BDNF in the hippocampus, as well as hippocampal neurogenesis. Physical exercise is one particularly effective strategy for increasing circulating levels of BDNF and improving brain function.

2In addition, studies also show that BDNF is an important regulator of synaptic transmission and long-term potentiation (LTP) in the hippocampus and in other brain regions. The effects of BDNF on LTP are mediated by the TrkB receptor. Especially in the hippocampus, this neurotrophin is thought to act on both the pre- and post-synaptic compartments, modulating synaptic efficacy, either by changing the pre-synaptic transmitter release, or by increasing post-synaptic transmitter sensitivity to induce a long-lasting increase in synaptic plasticity. Additionally, converging data now suggest a role for BDNF in the pathophysiology of brain-associated illnesses. Deficits in BDNF signaling are reported to contribute to the pathogenesis of several major diseases, such as Huntington’s disease, Alzheimer’s disease (AD), depression, schizophrenia, bipolar, and anxiety disorders. Thus, manipulating the BDNF signaling may present a viable approach to treat a variety of neurological and psychiatric disorders. BDNF protein is also detectable outside of the nervous system in several non-neuronal tissues, such as in endothelial cells, cardiomyocytes, vascular smooth muscle cells, leukocytes, platelets, and megakaryocytes. Therefore, it may also be involved in cancer, angiogenesis, reduction of glucose production from the liver, and in the uptake of glucose in peripheral tissues (see for review). In addition, BDNF promotes the development of neuromuscular synapses and is required for fiber-type specification, suggesting a potential role as a therapeutic target in muscle diseases. In this review, first we examine the currently known mechanisms of BDNF signaling, information essential for the creation of BDNF-based therapeutics. Next, we focus on the effects of antidepressants on BDNF-mediated plasticity. Additionally, we highlight the function of BDNF as a potent factor capable of conferring protection against neurodegeneration. Finally, we touch on the newly emerging role of BDNF in the pathogenesis of brain gliomas.

2.1. BDNF Transcripts

3The BDNF gene codes for a neurotrophin that is highly expressed in the CNS. At the beginning of 2000s, the only data available about the structure and regulation of the BDNF gene were from Timmusk and colleagues, which identified in rats four 5’ exons linked to separate promoters and one 3’ exon encoding the preproBDNF protein. These four BDNF promoters owned multiple points of BDNF mRNA regulation and suggested an activity-dependent regulation. Further studies, published in 2007, clarified that BDNF has a complex gene structure with 11 different exons in humans, nine different exons in rodents, and nine alternative promoters for both groups. Despite this complexity, the coding sequence is located in exon IX in both human and rodents. The latter includes the common sequence that encodes for the proBDNF protein. All other exons are untranslated regions with a start codon present in exons I, VII, VIII, and IX of the human BDNF gene. Exon IX is present in all BDNF mRNA isoforms. It is supposed that the nine alternative promoters can regulate the complex spatio-temporal expression of BDNF gene and allow BDNF to respond to a greater variety of stimuli. For instance, in human brain tissues, all exons are expressed, but to different degrees and in different brain structures. Human heart tissue, instead, expresses high levels of BDNF isoforms containing exon IV and exon IX.

4Currently, two BDNF promoters, promoter I and promoter IV, have been well characterized for their response after the activation of the L-type voltage gated calcium channel (L-VGCC) or the n-methyl-d-aspartate (NMDA) receptor. Activation of L-VGCC and NMDA receptors mediate intracellular Ca2+-signaling and regulate several aspects of brain functions (for review). Promoter I is more responsive to neuronal activity and induces activity-dependent expression of BDNF in vitro and in vivo. It contains calcium-responsive elements (CaREs) and cyclic adenosine monophosphate (cAMP)/calcium response element (CRE). Deletion of CRE or overexpression of dominant negative of CREB (cAMP-response element-binding protein) significantly impairs rat BDNF promoter I response to neuronal depolarization. Human BDNF promoter I is similar to rat promoter, since an orthologous CRE-like element is also present. However, mutation of this site did not affect human BDNF promoter I response to depolarization. Human BDNF promoter I also contains an activator protein 1 (AP1) -like element and an asymmetric E-box-like element. Mutation in E-box-like element reduces human BDNF promoter I induction, impairing the response to neuronal depolarization.

5Another highly characterized BDNF promoter is the BDNF promoter IV that contributes significantly to activity-dependent BDNF transcription. Human and rat BDNF promoter IV are similar. In this promoter, three CaREs and three other regulatory elements involved in regulating rat BDNF promoter response to NMDA receptor activation have been identified. NMDA receptor activation is capable of triggering BDNF exon IV transcription through a protein-signaling cascade requiring extracellular signal-regulated kinase (ERK), Ca2+/calmodulin-dependent protein kinase (CaMK) II/IV, phosphoinositide 3-kinases (PI3K), and phospholipase C (PLC). BDNF exon IV expression also seems capable of further stimulating its own expression through TrkB activation. Additionally to the CaREs, two positive regulators have been identified: the NF-kB (nuclear factor kappa-light-chain-enhancer of activated B cells) and NFAT (nuclear factor of activated T-cells) binding sites. In contrast to these positive regulators, BDNF promoter IV also contains a negative regulatory element, the class B E-box. This is a binding site for a basic helix-loop-helix protein, BHLHB2, a suppressor of the bHLH gene superfamily. NMDA treatment is able to remove BHLHB2 binding to the E-box and to increase rat BDNF promoter IV activity. Disruption of BDNF promoter IV in mice significantly reduced the number of parvalbumin GABAergic neurons in the prefrontal cortex and impaired GABAergic activity. These mice displayed depression-like behavior such as anhedonia-like behavior and increased latency to escape in the learned helplessness test. Further evidence suggests a relationship between stress exposure and epigenetic regulation of BDNF promoter IV with the development of psychiatric disorders. Specifically, changes in BDNF promoter IV methylation levels are implicated in depression. Preliminary evidence has demonstrated that patients with major depressive disorder (MDD) present a hypomethylation of the CpG-87 site of the promoter IV region of BDNF gene and are less likely to benefit from antidepressants. In addition, BDNF disruption from promoter IV-derived transcripts impairs fear expression in mice, suggesting that cells expressing BDNF from promoter IV critically regulate hippocampal-prefrontal plasticity during fear memory.

2.2. miRNAs and BDNF

6MicroRNAs (miRNAs) are a class of evolutionary conserved small non-coding single-strand RNA molecules, 18–25 nucleotide long, able to bind to 3′ untranslated regions (3′ UTR) of target mRNAs and promote their degradation or suppress their translation into proteins. MiRNAs are expressed abundantly within the nervous system in a tissue-specific manner and are crucial players in several biological processes, including neurogenesis, neuronal maturation, synapse formation, axon guidance, neurite outgrowth and neuronal plasticity. Accumulating data indicate that synthesis of BDNF may be affected by miRNAs, indeed, a regulatory negative feedback loop between BDNF and miRNAs exists. That is, while BDNF treatment stimulates neuronal miRNAs expression, miRNAs generally inhibit the expression of BDNF. This negative feedback loop is maintained in a state of equilibrium in normal cells. Alterations in miRNAs or in BDNF contribute to the pathogenic mechanisms involved in neurodegenerative diseases or neuropsychiatric disorders.

7A number of recent studies, obtained from high throughput sequencing screening of different brain regions or from neurological disorders, have identified seven miRNAs (miR-15a, miR-206, miR-155-5p, miR-16, miR-103-3p, miR-330-3p, Let-7a-3p) correlated with BDNF. Previous data published by Schratt et al. reported the involvement of miR-134 in BDNF-regulated dendritic spine size in hippocampal neurons. They demonstrate that miR-134 negatively regulates the spine size via repressing the translation of LIM kinase 1, which is known to regulate dendritic structures. BDNF is able to relieve the inhibition of LIM kinase 1 translation, and in this manner contribute to synaptic development, maturation and/or plasticity. Recently, Baby et al. found that miR-134 mediates post-transcriptional regulation of CREB1 and BDNF, as previously described by Gao et al., who demonstrated that mutant mice lacking Sirtuin 1 (SIRT1) catalytic activity shows reduction in both CREB and BDNF proteins and upregulation of miR-134. Thus, higher levels of miR-134 negatively regulate synaptic plasticity. MiR-134-mediated post-transcriptional regulation of CREB1 and BDNF prevents cognitive deficits in chronic unpredicted mild stress model (CUMS). At the same time, data published by Xin and coworkers demonstrate that miR-202-3p silencing reduces the damage to hippocampal nerve in CUMS rats through the upregulation of BNDF expression. miRNAs could be an effective target also for the treatment of depression. Recent data demonstrate that miR-124-mediated post-transcriptional regulation of CREB1 and BDNF can improve depression-like behavior in a rat model. Instead, miR-153 through the inhibition of activation of the JAK-STAT signaling pathway improves BDNF expression and influences the proliferative ability of hippocampal neurons in autistic mice.

8In vitro studies have also allowed analysis of the effect of neurotoxins or anesthetic agents on miRNAs expression and in turn, on BDNF expression. For instance, differentiated PC12 cells, treated with 1-methyl-4-phenylpyridinium (MPP), show upregulation of miR-34a, miR-141, and miR-9, suggesting that perturbed expression of them may contribute to Parkinson’s disease (PD)-related pathogenic processes, probably by affecting the expression of B-cell lymphoma 2 (BCL2), BDNF, and SIRT1 as potential targets.

9Instead, studies in vitro on embryonic stem cell-derived neurons demonstrated that inhibition of miR-375 and miR-107 ameliorates ketamine-induced neurotoxicity via inverse regulation of the BDNF gene.

10In summary, understanding the different functions of the various BDNF transcripts, the modulation of the expression of specific exons, and investigating the function of the BDNF-related miRNAs may represent a promising strategy to restore enduring changes in gene expression in response, for example, to environmental insults. This, in turn, might open new therapeutic perspectives for the treatment of neurodegenerative and neuropsychiatric disorders.

2.3. Biology of BDNF

11Synthesis and maturation of BDNF is a multistage process, involving the formation of several precursor isoforms. The BDNF protein, discovered in 1982, is a highly conserved protein of 247 amino acids, synthesized and folded in the endoplasmic reticulum as preproBDNF (32–35 kDa). Upon translocation to the Golgi apparatus, the signal sequence of the preregion is rapidly cleaved, and the isoform proBDNF (28–32 kDa) is generated. The proBDNF is further cleaved to reach the mature isoform (mBDNF, 13 kDa). Intracellular proteolytic cleavage of proBDNF may occur by the subtilisin-kexin family of endoproteases such as furin, or in intracellular vesicles by convertases (Figure 1).

12Extracellular cleavage of proBDNF is determined by plasmin and matrix metalloproteases 2 and 9 (MMP2 and MMP9). Depending on the cell type, BDNF can be secreted in a constitutive or activity-dependent manner. In neuronal cells, both proBDNF and mBDNF are released following cell membrane depolarization. The balance of proBDNF and mBDNF depends on the particular stages of brain development and regions. In the early postnatal period, the concentration of proBDNF is higher and may be considered as an important factor modulating brain function; while mBDNF prevails in adulthood and is important for processes occurring in adulthood, such as neuroprotection and synaptic plasticity. Both proBDNF and mBDNF are active, eliciting opposing effects via the p75 neurotrophin receptor (p75NTR), a member of the tumor necrosis factor (TNF) receptor family and TrkB receptor, respectively. In resting form, both types of receptor are located in the membrane of intracellular vesicles. Stimulation with cAMP, Ca2+, or electrical impulse initiates their transfer and fusion with the cellular membrane.

13The mature domain of proBDNF interacts preferentially with p75NTR, mediating synaptic pruning in the prenatal brain. ProBDNF, through its pro-domain, can also interact with the sortilin receptor or other vacuolar protein sorting 10 protein (Vps10p) (Figure 2). Thus, proBDNF binding to specific receptors triggers signaling pathways, which can determine neuronal fate via promoting their death or survival. The proBDNF/p75NTR/sortilin binding complex initiates signaling cascades leading to the activation of c-Jun amino terminal kinase (JNK). This pathway is involved in neuronal apoptosis. High levels of p75NTR expression are detected during brain development and post-traumatic recovery. When mature domain of BDNF binds to p75NTR, the RIP2 (serine/threonine-protein kinase 2)/TRAF6 (tumor necrosis factor receptor associated factor 6)-mediated pathway is initiated, which leads to NF-kB activation. The activation of NF-kB promotes neuronal survival and maintenance during brain development. In addition, p75NTR interacts also with the Ras homologous (Rho) protein family. This pathway is reported to regulate neuronal growth cone development and motility.

14mBDNF binds with the high-affinity TrkB receptor, the receptor dimerizes, and the intracellular tyrosine residues are autophosphorylated. Phosphorylated-TrkB activates several enzymes: PI3K, mitogen-activated protein kinase (MAPK), PLC-γ, and guanosine triphosphate hydrolases (GTP-ases) of the Rho gene family. mBDNF-TrkB-signaling pathways regulate multiple events, such as apoptosis and survival of neurons, dendritic growth, spine maturation and stabilization, development of synapses, learning- and memory-processes-dependent synaptic plasticity.

15PI3K/Akt-related pathway exerts antiapoptotic and pro-survival activity and modulates NMDA receptor-dependent synaptic plasticity. The PI3K/Akt/mTOR cascade enhances dendritic growth and branching through regulation of protein synthesis and cytoskeleton development.

16The MAPK/Ras-signaling cascade regulates protein synthesis during neuronal differentiation and is also required for the activation of ERK 1/2 and CREB. This pathway is crucial not only for early response gene expression (e.g., c-Fos), but also for cytoskeleton protein synthesis (e.g., Arc and cypin), as well as dendritic growth and branching in hippocampal neurons.

17The PLC-γ-dependent pathway evokes activation of CAM kinase and protein kinase C (PKC), which subsequently increases the 1,2-diacylglycerol (DAG) and Ca2+ ion concentrations. The PKC-dependent pathway is reported to enhance synaptic plasticity (Figure 2).

18In summary, the specific role of BDNF in the regulation of numerous brain physiological processes depends on the interaction of its isoforms with different types of receptors. This, in turn, elicits the activation of signaling pathways that are critical for processes of brain development, synaptic plasticity, and protection and/or regeneration after damage. Perturbation of the BDNF synthesis, resulting in dysfunctions of its signaling cascades, may be responsible for triggering several pathological processes.

2.4. The Human BDNF Variant Val66Met

19BDNF level in the peripheral tissues, brain, and blood may be also affected by gene polymorphism. The pro-domain of BDNF is the locus of a functional human BDNF polymorphism (SNPs) Val66Met, also known as rs6265 or G196Apolymorphism. This point mutation causes a substitution of Valine (Val) to Methionine (Met) at codon 66 (Val66Met) in the pro-domain of BDNF (Figure 1). The Val66Met polymorphism does not exist in the mouse or other model organisms. Thus, multiple studies aim to mimic the function of BDNF Val66Met in cellular models or in genetically engineered mouse models. The BDNF Val66Met variant was first identified in the late 1990s and in 2002 the first two genetic studies investigating the BDNF Val66Met polymorphism in the pathogenesis of neurodegenerative disease were published. The functionality of BDNF Val66Met variant was only confirmed in 2003, where BDNF Val66Met polymorphism was shown to disrupt the episodic memory in humans. In addition, Egan et al. also demonstrated that in hippocampal cultures BDNF Val66Met polymorphism did not alter BDNF expression per se, but the perisomatic localization of BDNF. Then, in 2005 it was discovered that the BDNF Val66Met substitution also disrupts the sortilin-binding site, impairing activity-mediated secretion of BDNF. Likewise, the BDNF Val66Met substitution also disrupts the translin-binding site, which impairs dendritic targeting of BDNF mRNA. Thus, the principle molecular mechanism associated with the BDNF Val66Met polymorphism is the deficient activity-dependent release of BDNF, which consequently impacts the efficiency of BDNF-TrkB signaling. Following the demonstration that this SNP was functionally relevant over the past 18 years, more than 1700 studies have investigated the effects of this polymorphism on brain function in health, as well as in diseases, particularly in neuropsychiatric disorders. The BDNF Val66Met polymorphism has been associated with cerebral cortex plasticity, with gray matter structures, or white matter integrities and structural networks. More specifically, BDNF Val66Met polymorphism is associated with cognitive processes, and cognitive impairment in neurodegenerative disease, such as Parkinson’s disease (PD) and AD, and even more with several brain disorders, including MDD and bipolar disorder, epilepsy, schizophrenia, aging and dementia and stroke. Met66, but not Val66, BDNF pro-domain can induce the growth cone retraction in young hippocampal neurons. Although many studies have demonstrated the possible genetic effects of this BDNF polymorphism in diseases or brain function, other articles have failed to replicate the findings. The discrepancies of BDNF Val66Met genetic studies may result from many factors such as environmental factors, ethnicity, age, and sex.

3.1. Major Depressive Disorder

20Major depressive disorder is one of the most prevalent and debilitating psychiatric disorders with high impact on the quality of life and negative effects on mood, behavior, and cognition. Over the past few decades, several mechanisms have been investigated in the pathophysiology of MDD, including altered serotonergic, noradrenergic, dopaminergic, and glutamatergic systems, increased inflammation, hypothalamic-pituitary-adrenal axis abnormalities, vascular changes, and decreased neurogenesis and neuroplasticity. In particular, a decrease in serotonergic neurotransmission is regarded as the main etiopathogenetic mechanism occurring in depressed patients. Thus, the most common drugs used to treat MDD are serotonin reuptake inhibitor (SSRI) that block SERT and thus increase serotonin in the raphe nucleus at post-synapse. Therefore, a misbalance in the serotonin production and/or release is believed to play a central role in determining MDD. This led to finding, by means of genetic, proteomic and pharmacological tools, molecules able to increase the expression of serotonin in neurons by modulating neural genes or proteins. Among these molecules, TPH2, the rate-limiting enzyme responsible for brain serotonin biosynthesis, plays a crucial role and is amenable of genetic and pharmacological manipulation. Nevertheless, in 1997 Duman and Nestler formulated the neurotrophin hypothesis of depression. This theory is now supported by studies demonstrating a decrease in BDNF mRNA and protein levels in postmortem critical regions, such as the hippocampus, prefrontal cortex and amygdala, in patients with MDD compared to controls.

3.2. BDNF and Neuronal Plasticity

21Brain development occurs through coordinated processes of neuro- and gliogenesis, formation of neuronal projections and synaptogenesis, and programmed cell death and elimination of improperly formed connections, together resulting in the formation of the functionally and morphologically adjusted structure of the adult brain. Neuroplasticity or brain plasticity is the ability of the nervous system to reorganize its structure, function, and connections in response to extrinsic or intrinsic stimuli. Neuronal plasticity in rodents has been well-documented during the last decades, whereas neuroplasticity in the human brain largely remains indirect, mostly because of methodological limitations as well as ethical constraints. Neuronal plasticity includes different mechanisms excellently reviewed by Castren. One of these is the neurogenesis, i.e., the formation of newborn neurons in proliferative areas. There is solid evidence that neurogenesis occurs in the adult mammalian brain. In rodent adult brains, neurogenesis is mainly restricted to the subventricular zone and the subgranular zone of the dentate gyrus in the hippocampus and olfactory bulbs. An accumulating body of evidence indicates that BDNF is involved in the regulation of migration of neuronal progenitors along the rostral migratory stream and neuronal settlement in the olfactory bulb and also acts during the later stages of neurogenesis.

22Neuronal plasticity is extensively studied during critical periods, a time window during the early phase of brain development, when neuronal circuits are noticeably sensitive to being shaped by external stimuli and experience, producing permanent and large-scale changes to neural circuits. The same circuits can be shaped by experience later in life, but to a lesser degree. After the ending of critical periods, neuronal plasticity and changes in network structure are more restricted. However, recent data indicate that several drugs used for the treatment of neuropsychiatric disorders can directly induce plasticity and reactivate a critical period-like plasticity in the adult brain. The first functional evidence for the role of neurotrophins in plasticity was obtained in the visual cortex. The observation that BDNF synthesis in the visual cortex is regulated by visual stimulation made BDNF the prime candidate for this activity-dependent regulated factor. In transgenic mice with early overexpression of BDNF, an accelerated onset and end of the critical period and precocious maturation of inhibitory circuits was observed. Conversely, mice raised in the dark and resulting in lower levels of BDNF showed a delayed visual plasticity. In addition, a disruption in the binding between promoter regions of BDNF exon IV and cAMP response element-binding protein (CREB) results in decreased inhibitory input, which impairs the critical period plasticity.

3.3. BDNF and Synaptic Plasticity

23Another mechanism involved in neuronal plasticity is the modification of mature neuronal morphology, involving axonal and dendritic arborization and pruning, an increase in spine density, and synaptogenesis. Epigenetic mechanisms involved in the transcriptional regulation of genes also can contribute to synaptic plasticity. Several in vitro and in vivo studies analyzed the effects of BDNF on plasticity. Cazorla et al. proved that 48 h of BDNF stimulation in PC12 cells, transfected with TrkB, increased neurite outgrowth compared to the non-treated cells. Interestingly, BDNF stimulation was able to promote dendritic outgrowth and spine formation in primary hippocampal cells grown in B27-deprived medium. This neuroplastic effect is probably achieved through the activation of intracellular-signaling cascades. Recent data suggest that intracellular overexpression of BDNF in hippocampal developing neurons induces maturation of excitatory and inhibitory synapses, with respect to exogenous application of BDNF. BDNF mice lacking BDNF die during the second postnatal week and BDNF deficit causes inhibition of dendritic arborization and reduction of expression of genes functionally related to vesicular trafficking and synaptic communication. Instead, heterozygous BDNF mice survive into adulthood and BDNF is required for several forms of LTP, the main mechanism mediating plasticity. At morphological level, these mice display a specific hippocampal volume reduction similar to that observed in heterozygous TrkB mice, but in contrast to p75NTR-deficient mice. These findings suggest a link between hippocampal volume and BDNF-mediated TrkB signaling. Over the last years, BDNF has been extensively studied as an important regulator of synaptic transmission and LTP in the hippocampus and in other brain regions. The effects of BDNF in LTP are mediated by TrkB receptors. In particular, in the hippocampus the neurotrophin is thought to act at pre- and post-synaptic levels, modulating synaptic efficacy either by changes in pre-synaptic transmitter release, or by increased post-synaptic transmitter sensitivity (see e.g.,) to induce a long-lasting increase in synaptic plasticity. This depends on individual circumstances. Thus, BDNF can be: (i) either, a mediator or a modulator of synaptic plasticity, (ii) both, a neurotransmitter that acts both at pre- and post-synaptic level simultaneously at the same individual synapse. Recent data published from Lin et al. revealed that in CA3 or CA1 regions anterograde BDNF-TrkB signaling is involved in LTP induction, while anterograde and retrograde BDNF-TrkB signaling contributes to LTP maintenance. BDNF in both pre-synaptic and post-synaptic terminals modulate basal neurotransmission and pre-synaptic TrkB, probably regulating pre-synaptic release. In addition, it has also been shown that BDNF regulates the transport of mRNAs along dendrites and their translation at the synapse. These processes occur by modulating the initiation and elongation phases of protein synthesis, and by acting on specific miRNAs. Local protein synthesis responds with rapid and subtle modulation of the proteome to remodel the synaptic regions in response to stimuli. Protein turnover is required for synaptic plasticity, and BDNF-signaling has been also described as a crucial regulator for maintaining the baseline autophagic activity in the brain. BDNF deficiency causes an uncontrolled rise in autophagic degradation.

24BDNF is one of the most studied synaptic molecules that efficiently modify synaptic strength and can act as a mediator, modulator, or instructor of synaptic plasticity. Specific changes in dendritic spines, as well as in adult hippocampal neurogenesis, can be correlated to several forms of learning and memory. BDNF is one of the most inspiring molecules to better understand the disadvantageous synaptic learning underlying the etiology of depression, accompanied by declines in the rate of adult neurogenesis and in spine densities.

3.4. BDNF in Depressed Patients

25BDNF protein and TrkB receptor are detectable in several non-neuronal tissues, including endothelial cells, cardiomyocytes, vascular smooth muscle cells, leukocytes, megakaryocytes, and platelets. Serum BDNF has been clearly demonstrated to originate from the progenitors of platelets. Platelets are the major source of peripheral BDNF and are important for storing the BDNF secreted from other tissues. Over the last years, there has been a great interest in peripheral BDNF measures in relation to psychiatric illness. It has been studied as biomarker reflecting these disorders. However, there is no evidence that serum BDNF is related to brain BDNF and neuroplasticity. Nevertheless, the low serum concentration of BDNF has often been associated with the pathophysiology of MDD. An aspect to consider is if the serum BDNF levels are dependent on the release of BDNF from platelets. The significance of the lower BDNF levels in depression is currently unclear. The temporal correlation between serum BDNF levels and the antidepressant effect seems to be indirect: ketamine and electroconvulsive shock treatment increase serum BDNF levels only gradually, while their antidepressant effect appears quickly. There are two studies that directly observed a reduction of BDNF levels in platelets of patients with MDD. Another study showed that BDNF levels of platelet were significantly decreased compared to the controls. In this study, the BDNF levels were normalized compared to control with SSRIs treatment. Taken together, these studies strongly suggest that changes in serum BDNF levels reflect altered BDNF release from blood platelets. Thus, given the similarities in the regulation of BDNF synthesis between megakaryocytes and neurons, there may be parallels between the brain, BDNF in serum, and release. Nevertheless, within the CNS a reduction in BDNF and TrkB expression has been reported in the hippocampus and prefrontal cortex of post-mortem brain tissues of suicide victims. In addition, several meta-analyses data confirm the association of the Val66Met polymorphism with an increase of susceptibility to develop mood disorders. Finally, a recent paper showed that subjects with the Met allele of the BDNF gene are more likely to develop depression.

26A disruption in serotonin signaling in the brain is also believed to be involved in the pathophysiology of depression. Changes in synaptic serotonin levels and receptor levels are coupled with altered synaptic plasticity and neurogenesis. It has been proposed that chronic treatment with conventional antidepressants, such as SSRIs, but not acute administration increases neurogenesis and selective SSRIs might reactivate serotonin’s ability to mediate developmental plasticity. BDNF acts as a modulator of the 5-HT system and vice versa, acting as the link between the antidepressant drug and the neuroplastic changes. Close molecular connections between serotonin receptors and neurotrophic proteins such as BDNF and intracellular signaling cascades are responsible for cytoskeletal rearrangement. Thus, dysregulation in 5-HT–BDNF interaction may be responsible for the development of neuropsychiatric and behavioral abnormalities.

27Understanding the function of the members of the BDNF system in response to the challenges of the environment and the interaction with different 5-HT receptors in health and disease will lead to new classes of drugs that could be used in therapy for psychiatric and neurodegenerative disorders.

3.5.1. BDNF and Antidepressant Treatments

28Multiple lines of evidence suggest that antidepressant treatments increase BDNF mRNA and protein levels in the cerebral cortex and hippocampus (for review see). This increase is partly due to a reduction of histone acetylation in the BDNF promoter regions. The involvement of BDNF in the efficacy of antidepressant treatments has mainly been demonstrated in rodent models. It has been demonstrated that all pharmacological classes of clinical antidepressants increase TrkB autophosphorylation and signaling in the hippocampus and forebrain, effects observed within hours after the administration of the drug. Similar results in BDNF mRNA and TrkB phosphorylation have been observed after acute treatment with ketamine. In rodents, injection of BDNF in the hippocampus reduces depression-like behavior, in contrast injection of BDNF into the nucleus accumbens or ventral tegmental area promotes depressive effects, demonstrating the network-dependent effect of BDNF in mood regulation. Interestingly, conditional knockout of BDNF in forebrain regions increases depressive behavior in females, but not in male mice, and blocks the effects of antidepressants desipramine or ketamine. Similarly, conditional deletion of TrkB in dentate gyrus or inhibition of TrkB signaling by a dominant-negative TrkB receptor blocks the effects of antidepressants. In addition, mice with Val66Met polymorphism are insensitive to antidepressants. Recent evidence demonstrates that the antidepressant effects of GLYX-13, a novel glutamatergic compound that acts as an NMDA modulator with glycine-like partial agonist properties, are blocked by intra-medial prefrontal cortex infusion of an anti-BDNF antibody or in mice with a knock-in of the BDNF Val66Met allele. Pharmacological inhibition of BDNF-TrkB signaling or L-type voltage-dependent Ca2+ channels (VDCCs) blocks the antidepressant behavioral actions of GLYX-13.

29Taken together, these data suggest that BDNF serves as a transducer, acting as the link between the antidepressant drug and the neuroplastic changes that result in the improvement of depressive symptoms.

3.5.2. Beneficial Effects of Exercise on Plasticity: The Role of BDNF

30Several lines of evidence suggest that exercise has beneficial effects on plasticity and BDNF could be a link between plasticity and physical activity. Although it has been proven that exercise in MDD patients reduced depressive symptoms, neuroplasticity per se has not yet been monitored in these patients. However, voluntary physical exercise, like an enriched environment, increases expression of BDNF in the hippocampus, as well as hippocampal neurogenesis and this could improve brain function by enhancing plasticity, cognition, learning, and memory. Physical exercise is one particularly effective strategy for increasing circulating levels of BDNF. It has repeatedly been demonstrated that an acute bout of aerobic exercise transiently increases both serum and plasma BDNF in an intensity-dependent manner. Exercise increases the release of BDNF from the human brain suggesting that exercise also mediates central BDNF production in humans. It has been suggested that miR-34a potentially can also mediate changes in BDNF expression and may reflect the decrease in performance after overtraining.

31Multiple studies suggest that BDNF has a dominant role in mediating the effects of physical activity on cognitive changes. It has been shown that three months of aerobic exercise training increases hippocampal volume in healthy individuals and in patients with schizophrenia by 12% and 16%, respectively. The question whether exercise regulates muscle-derived circulating factors that can pass through the blood–brain barrier and stimulate BDNF production in the brain remains unclear. In 2016, Moon et al. show that the myokine cathepsin B (Ctsb) might be involved in mediating the exercise-induced improvement in hippocampal neurogenesis, memory, and learning. Mice lacking Ctsb showed depression-like symptoms when they were forced to swim.

32Other papers have demonstrated that exercise induces upregulation in skeletal muscle of PGC1α, a transcriptional co-activator of mitochondrial biogenesis and oxidative metabolism in brown adipose tissue and muscle. In muscle, the increase of PGC1α expression stimulates an upregulation of FNDC5, a membrane protein that is cleaved and secreted into the circulation as the myokine irisin. FNDC5 cross the blood–brain barrier inducing BDNF expression in the hippocampus, in this way BDNF plays a role in neurogenesis and reward-related learning and motivation. Current research has also shown that high intensity exercise increases peripheral lactate and BDNF levels; at the same time lactate infusion at rest can increase peripheral and central BDNF levels. Lactate and BDNF can induce neuroplasticity. In addition, acute elevation of BDNF did not compensate for hypoxia-induced cognition impairment.

33The identification of exercise-related factors that have a direct or indirect effect on brain function has the potential to highlight novel therapeutic targets for neurodegenerative diseases.

4. The Protective Role of BDNF on Neurodegeneration

34Neurodegenerative diseases comprise a wide range of neurological diseases such as AD, PD, Huntington’s disease, and amyotrophic lateral sclerosis (ALS), characterized by the deterioration and then the death of selective nuclei of neurons in the brain or the spinal cord. They are chronic and progressive diseases, currently incurable and highly debilitating, causing a tremendous emotional and economic burden on patients, their families, and society. AD, the most frequent among neurodegenerative diseases, accounts for about 70% of dementia cases all over the world, that is about 35 million people. It is estimated to cost more than 480 billion euros each year throughout the world (Sources: OMS, EBC (European Brain Council)). Currently, no pharmacological treatment is available to cure or even significantly slow down the course of neurodegenerative diseases. For these reasons, experimental findings showing that physical exercise, exposure to an enriched environment, metabolic changes and nutritional and/or cognitive intervention, may exert a protective role on neurodegeneration either by delaying the onset and/or curbing the course of the disease, raise hope that these new tools might be useful also in clinical practice. BDNF appears to be crucial or, in some cases even essential, to mediate the neuroprotective effects of the above-mentioned environmental stimuli (Figure 3). In particular, as discussed above, it is well established that BDNF accounts for the hippocampal adult neurogenesis, which, in turn, can be stimulated by a number of conditions such as physical exercise, enriched environment, hormonal balance (i.e., steroid hormones such a cortisol and testosterone) and nutritional intervention (i.e., fasting, low-calorie intake, low-carb diet, selective nutrient intakes), capable of increasing the BDNF level.

4.1. The Protective Role of BDNF on Alzheimer’s Disease

35A reduced level of BDNF has been found in patients affected by neurodegenerative diseases such as Parkinson’s, Huntington’s and Alzheimer’s disease as well as in mild cognitive impairment, the latter being a prodromal stage of AD, characterized by a slight decline of cognitive abilities including memory, thinking and judging skills. In some instances, the levels of BDNF even correlate with the severity of the diseases, pointing towards a pathogenetic link between BDNF and AD. Although there are some papers reporting an increase of BDNF in serum or in the post-mortem brain, this might be due either to compensatory mechanisms or its release from immune cells or pharmacological treatments known to raise BDNF (i.e., antidepressants).

36Recently, a very complex study explored the role of physical activity in a genetic mouse model of AD. This study provided the most compelling evidence of the relationship between physical activity, adult hippocampal neurogenesis, BDNF, and AD. This study elegantly confirms that adult hippocampal neurogenesis plays a pivotal role in brain resilience to AD. They manipulated with pharmacological and genetic tool neurogenesis as well as BDNF, clearly showing that physical exercise needs neurogenesis to protect the brain from AD and that BDNF is essential for such a protection. In addition, it provides evidence that adult hippocampal neurogenesis can counteract AD memory impairment, only in combination with BDNF, whereas if neurogenesis is experimentally blocked, BDNF does not exert beneficial effects. Finally, pharmacological increase of BDNF further ameliorates AD pathology. Thus, agents that promote both BDNF signaling and neurogenesis might be the key to preventing or curing AD. As far as metabolism is concerned, it has been shown that intermitting fasting, by causing a transition from utilization of carbohydrate and glucose to a fatty acid and ketones source of energy (refer to as “G-K shift”) generates a number of beneficial cognitive, metabolic, and cardiovagal effects. BDNF is increased upon intermitting fasting and mediates at least part of these effects. Its increase is stimulated by the ketone body, β-hydroxybutyrate that inhibits histone deacetylases that repress BDNF promoters. Recently, the role of BDNF and neuroprotection in the context of metabolism and fasting has been nicely reviewed by Mattson et al..

4.2. BDNF and Ras-ERK-CREB Signaling in Alzheimer’s Disease

37BDNF, as also discussed above, causes the activation of the Ras-ERK signaling cascade leading to the phosphorylation of CREB. Such a pathway exerts a well-known trophic and protective role on neuronal cells both in vitro and in vivo in a variety of neurodegenerative models, including AD, PD, and Huntington’s diseases. Nevertheless, it has become clear that the Ras-ERK pathway may also foster neurodegeneration or hamper the action of neurotrophic factors when activated by noxious stimuli as occurs for instance in PD and AD. In particular, it has been shown in a number of different cellular models such as primary cortical rat neurons, rat B103 neuroblastoma cells, and A1 mouse mesencephalic cells, that APP and/or Aβ42 oligomer induces the activation of Ras-ERK and GSK-3 signaling, that, in turn, causes hyperphosphorylation of tau and APP at Thr668. The involvement of these molecular events in the pathogenesis AD is corroborated by the finding that activation of Ras-ERK and GSK-3 correlates with Aβ levels in the brain of AD patients. Aberrant stimulation of Ras-ERK signaling forces neurons to enter the cell cycle as shown by the expression and nuclear accumulation of cyclin D1 and the subsequent G1/S progression. Since neurons lack functional cell cycle machinery, these events lead to cell death (i.e., mitotic catastrophe) instead of cell division. Interestingly, as clearly shown in the mouse model of familial AD APPswe/PS1ΔE9 mice, although ERK phosphorylation is enhanced compared to the wild type counterpart, it does not result in normal CREB phosphorylation. The impairment in CREB signaling parallels to impairment in a number of cognitive tests. Therefore, in AD, BDNF downregulation is mediated by the impairment of CREB signaling caused by amyloid β (Figure 3).

5. BDNF and Brain Cancer: An Unexpected Role. An Oncogene or a Tumor Suppressor?

38The role of BDNF and its cognate receptor TrkB in cancer, including brain cancer, has been recognized for a long time. In many types of cancers, BDNF and/or TrkB have been found expressed or in some cases over-expressed. This is not surprising since growth factors, including neurotrophic factors, and their tyrosine kinase receptors have long been involved in tumors with different cell-dependent mechanisms, fostering proliferation, enhancing anti-apoptotic signaling, and making cells unresponsive to anti-proliferative stimuli. The direct oncogenic activity of TrkB might also be due to the crosstalk with EGF receptors that together with its ligand is well-known to promote cell transformation. BDNF administration not only does phosphorylate TrkB but also EGFR. In line with these observations, it has been recently shown that BDNF produced by glioblastoma (GBM) differentiated cells acts on GBM stem cells, fostering their growth through paracrine signaling.

39However, recently another study showed that exposing mice to an enriched environment is able to decrease the growth of intracranial glioma, decreasing proliferation and invasion, and improving overall survival. Such an effect is achieved by means of both indirect and direct mechanisms. The former acts via natural killer cells of the innate immune system, whereas the latter utilizes BDNF stimulation of its truncated receptor TrkB.T1 on glioma cancer cells. BDNF binding the TrkB.T1 receptor signals to the Rho protein dissociation inhibitor (RhoGDI), the latter detaches from TrkB.T1 and binds to the small G protein RhoA, leading to its inhibition. The authors found that an enriched environment causes the synthesis of IL-15 and BDNF. When mice bearing the glioma and not housed in enriched environments were infused with BDNF, they reduced tumor size and macrophage infiltration. Thus, showing that at least in part, BDNF accounts for the oncolytic effect elicited by the enriched environment. In a more recent study, the same group delved deeper into the mechanisms, finding that enriched environment changes glioma-associated myeloid cells. BDNF plays a central role by stimulating the production of IL-15 in microglia, which in turn stimulates the natural killer cells to produce IFN-γ. Natural killer cells were responsible for the switch to an oncolytic environment (Figure 3).

40Taken together, a scenario emerges where BDNF, acting on different cells is able to reorganize the brain microenvironment in such a way that it becomes resilient to neurodegeneration or oncolytic for tumors. In this regard, although supported by much more preliminary data, it seems that also other compounds might share these properties.

6. Conclusions

41In this review, we discussed the role of BDNF in neurogenesis, differentiation, survival, synaptic plasticity, and transmission to reorganize the brain microenvironment. All BDNF gene products, such as proBDNF, mature BDNF, and even the isolated proBDNF domain, are known to exert functional activity. One of the most important features of BDNF is that it can act as a local, paracrine and/or autocrine factor, on both pre-synaptic and post-synaptic target sites. Here, we presented the contribution of altered BDNF signaling in the pathophysiology of brain diseases, including mental disorders (i.e., depression), neurodegenerative diseases, (i.e., Alzheimer’s disease), and brain tumor (i.e., glioblastoma). BDNF is one of the best-studied synaptic molecules that efficiently modify synaptic strength and it can act as a mediator, modulator, or instructor of synaptic plasticity. In neurons, the cellular processes that regulate the amount of both BDNF mRNA and protein, the changes in the efficiency of secretion, and transport of BDNF protein may affect synaptic function and cell survival. BDNF is one of the most inspiring molecules to better understand the disadvantageous synaptic learning underlying the etiology of depression, accompanied by the decline in the rate of adult neurogenesis and in spine densities. Furthermore, BDNF appears to exert a potent role in neuroprotection and/or brain regeneration by modulating signaling pathways such Ras-ERK-CREB, thus rendering neuronal cells resilient to neurodegeneration. Finally, BDNF appears to be crucial in the pathogenesis and development of brain tumors such as glioblastoma by reorganizing its microenvironment. Thus, understanding the physiologic and pathologic BDNF signaling and finding tools to modulate its expression (mRNA and/or protein) is a prerequisite for a potential BDNF-based therapy.

References 262

1.
Andreska T., Aufmkolk S., Sauer M., Blum R. High abundance of BDNF within glutamatergic presynapses of cultured hippocampal neurons. Front. Cell Neurosci. 2014;8:107.
Not in our library10.3389/fncel.2014.00107
2.
Clarke L.E., Liddelow S.A., Chakraborty C., Münch A.E., Heiman M., Barres B.A. Normal aging induces A1-like astrocyte reactivity. Proc. Natl. Acad. Sci. USA. 2018;115:E1896-E1905.
Not in our library10.1073/pnas.1800165115
3.
Parkhurst C.N., Yang G., Ninan I., Savas J.N., Yates J.R., Lafaille J.J., Hempstead B.L., Littman D.R., Gan W.B. Microglia promote learning-dependent synapse formation through brain-derived neurotrophic factor. Cell. 2013;155:1596-1609.
Not in our library10.1016/j.cell.2013.11.030
4.
Bartkowska K., Paquin A., Gauthier A.S., Kaplan D.R., Miller F.D. Trk signaling regulates neural precursor cell proliferation and differentiation during cortical development. Development. 2007;134:4369-4380.
Not in our library10.1242/dev.008227
5.
Regulation of Neurogenesis by Neurotrophins during Adulthood: Expected and Unexpected Roles · 2016
No notice
6.
Mattson M.P., Moehl K., Ghena N., Schmaedick M., Cheng A. Intermittent metabolic switching, neuroplasticity and brain health. Nat. Rev. Neurosci. 2018;19:63-80.
Not in our library10.1038/nrn.2017.156
7.
Actions of Brain-Derived Neurotrophin Factor in the Neurogenesis and Neuronal Function, and Its Involvement in the Pathophysiology of Brain Diseases · 2018
No notice
8.
Loprinzi P.D., Day S., Deming R. Acute Exercise Intensity and Memory Function: Evaluation of the Transient Hypofrontality Hypothesis. Medicina (Kaunas). 2019;55:445.
Not in our library10.3390/medicina55080445
9.
Fabel K., Wolf S.A., Ehninger D., Babu H., Leal-Galicia P., Kempermann G. Additive effects of physical exercise and environmental enrichment on adult hippocampal neurogenesis in mice. Front. Neurosci. 2009;3:50.
Not in our library10.3389/neuro.22.002.2009
10.
Knaepen K., Goekint M., Heyman E.M., Meeusen R. Neuroplasticity-exercise-induced response of peripheral brain-derived neurotrophic factor: A systematic review of experimental studies in human subjects. Sports Med. 2010;40:765-801.
Not in our library10.2165/11534530-000000000-00000
11.
Szuhany K.L., Bugatti M., Otto M.W. A meta-analytic review of the effects of exercise on brain-derived neurotrophic factor. J. Psychiatr. Res. 2015;60:56-64.
Not in our library10.1016/j.jpsychires.2014.10.003
12.
van Praag H., Shubert T., Zhao C., Gage F.H. Exercise enhances learning and hippocampal neurogenesis in aged mice. J. Neurosci. 2005;25:8680-8685.
Not in our library10.1523/jneurosci.1731-05.2005
13.
Tuon T., Souza P.S., Santos M.F., Pereira F.T., Pedroso G.S., Luciano T.F., De Souza C.T., Dutra R.C., Silveira P.C., Pinho R.A. Physical Training Regulates Mitochondrial Parameters and Neuroinflammatory Mechanisms in an Experimental Model of Parkinson’s Disease. Oxid. Med. Cell. Longev. 2015;2015:261809.
Not in our library10.1155/2015/261809
14.
Vilela T.C., Muller A.P., Damiani A.P., Macan T.P., da Silva S., Canteiro P.B., de Sena Casagrande A., Pedroso G.D.S., Nesi R.T., de Andrade V.M., et al. Strength and Aerobic Exercises Improve Spatial Memory in Aging Rats Through Stimulating Distinct Neuroplasticity Mechanisms. Mol. Neurobiol. 2017;54:7928-7937.
Not in our library10.1007/s12035-016-0272-x
15.
Itami C., Kimura F., Kohno T., Matsuoka M., Ichikawa M., Tsumoto T., Nakamura S. Brain-derived neurotrophic factor-dependent unmasking of "silent" synapses in the developing mouse barrel cortex. Proc. Natl. Acad. Sci. USA. 2003;100:13069-13074.
Not in our library10.1073/pnas.2131948100
16.
Edelmann E., Lessmann V., Brigadski T. Pre-and postsynaptic twists in BDNF secretion and action in synaptic plasticity. Neuropharmacology. 2014;76 Pt C:610-627.
Not in our library10.1016/j.neuropharm.2013.05.043
17.
Nakahashi T., Fujimura H., Altar C.A., Li J., Kambayashi J., Tandon N.N., Sun B. Vascular endothelial cells synthesize and secrete brain-derived neurotrophic factor. FEBS Lett. 2000;470:113-117.
Not in our library10.1016/s0014-5793(00)01302-8
18.
Wang H., Ward N., Boswell M., Katz D.M. Secretion of brain-derived neurotrophic factor from brain microvascular endothelial cells. Eur. J. Neurosci. 2006;23:1665-1670.
Not in our library10.1111/j.1460-9568.2006.04682.x
19.
Pius-Sadowska E., Machaliński B. BDNF-A key player in cardiovascular system. J. Mol. Cell. Cardiol. 2017;110:54-60.
Not in our library10.1016/j.yjmcc.2017.07.007
20.
Anders Q.S., Ferreira L.V.B., Rodrigues L.C.M., Nakamura-Palacios E.M. BDNF mRNA Expression in Leukocytes and Frontal Cortex Function in Drug Use Disorder. Front. Psychiatry. 2020;11:469.
Not in our library10.3389/fpsyt.2020.00469
21.
Brain-derived Neurotrophic Factor in Megakaryocytes · 2016
No notice
22.
Amadio P., Sandrini L., Ieraci A., Tremoli E., Barbieri S.S. Effect of Clotting Duration and Temperature on BDNF Measurement in Human Serum. Int. J. Mol. Sci. 2017;18:1987.
Not in our library10.3390/ijms18091987
23.
Meek T.H., Wisse B.E., Thaler J.P., Guyenet S.J., Matsen M.E., Fischer J.D., Taborsky G.J., Schwartz M.W., Morton G.J. BDNF action in the brain attenuates diabetic hyperglycemia via insulin-independent inhibition of hepatic glucose production. Diabetes. 2013;62:1512-1518.
Not in our library10.2337/db12-0837
24.
Marosi K., Mattson M.P. BDNF mediates adaptive brain and body responses to energetic challenges. Trends Endocrinol. Metab. 2014;25:89-98.
Not in our library10.1016/j.tem.2013.10.006
25.
Delezie J., Weihrauch M., Maier G., Tejero R., Ham D.J., Gill J.F., Karrer-Cardel B., Rüegg M.A., Tabares L., Handschin C. BDNF is a mediator of glycolytic fiber-type specification in mouse skeletal muscle. Proc. Natl. Acad. Sci. USA. 2019;116:16111-16120.
Not in our library10.1073/pnas.1900544116
26.
Tettamanti G., Cattaneo A.G., Gornati R., de Eguileor M., Bernardini G., Binelli G. Phylogenesis of brain-derived neurotrophic factor (BDNF) in vertebrates. Gene. 2010;450:85-93.
Not in our library10.1016/j.gene.2009.07.023
27.
Metsis M., Timmusk T., Arenas E., Persson H. Differential usage of multiple brain-derived neurotrophic factor promoters in the rat brain following neuronal activation. Proc. Natl. Acad. Sci. USA. 1993;90:8802-8806.
Not in our library10.1073/pnas.90.19.8802
28.
Timmusk T., Lendahl U., Funakoshi H., Arenas E., Persson H., Metsis M. Identification of brain-derived neurotrophic factor promoter regions mediating tissue-specific, axotomy-, and neuronal activity-induced expression in transgenic mice. J. Cell Biol. 1995;128:185-199.
Not in our library10.1083/jcb.128.1.185
29.
Timmusk T., Palm K., Metsis M., Reintam T., Paalme V., Saarma M., Persson H. Multiple promoters direct tissue-specific expression of the rat BDNF gene. Neuron. 1993;10:475-489.
Not in our library10.1016/0896-6273(93)90335-o
30.
Vashishta A., Habas A., Pruunsild P., Zheng J.J., Timmusk T., Hetman M. Nuclear factor of activated T-cells isoform c4 (NFATc4/NFAT3) as a mediator of antiapoptotic transcription in NMDA receptor-stimulated cortical neurons. J. Neurosci. 2009;29:15331-15340.
Not in our library10.1523/jneurosci.4873-09.2009
31.
Volpicelli F., Caiazzo M., Greco D., Consales C., Leone L., Perrone-Capano C., Colucci D’Amato L., di Porzio U. Bdnf gene is a downstream target of Nurr1 transcription factor in rat midbrain neurons in vitro. J. Neurochem. 2007;102:441-453.
Not in our library10.1111/j.1471-4159.2007.04494.x
32.
Mouse and rat BDNF gene structure and expression revisited · 2006
No notice
33.
Dissecting the human BDNF locus: Bidirectional transcription, complex splicing, and multiple promoters · 2007
No notice
34.
Paoletti P., Bellone C., Zhou Q. NMDA receptor subunit diversity: Impact on receptor properties, synaptic plasticity and disease. Nat. Rev. Neurosci. 2013;14:383-400.
Not in our library10.1038/nrn3504
35.
Simms B.A., Zamponi G.W. Neuronal voltage-gated calcium channels: Structure, function, and dysfunction. Neuron. 2014;82:24-45.
Not in our library10.1016/j.neuron.2014.03.016
36.
Shieh P.B., Hu S.C., Bobb K., Timmusk T., Ghosh A. Identification of a signaling pathway involved in calcium regulation of BDNF expression. Neuron. 1998;20:727-740.
Not in our library10.1016/s0896-6273(00)81011-9
37.
Tao X., Finkbeiner S., Arnold D.B., Shaywitz A.J., Greenberg M.E. Ca2+ influx regulates BDNF transcription by a CREB family transcription factor-dependent mechanism. Neuron. 1998;20:709-726.
Not in our library10.1016/s0896-6273(00)81010-7
38.
Tabuchi A., Sakaya H., Kisukeda T., Fushiki H., Tsuda M. Involvement of an upstream stimulatory factor as well as cAMP-responsive element-binding protein in the activation of brain-derived neurotrophic factor gene promoter I. J. Biol. Chem. 2002;277:35920-35931.
Not in our library10.1074/jbc.m204784200
39.
Pruunsild P., Sepp M., Orav E., Koppel I., Timmusk T. Identification of cis-elements and transcription factors regulating neuronal activity-dependent transcription of human BDNF gene. J. Neurosci. 2011;31:3295-3308.
Not in our library10.1523/jneurosci.4540-10.2011
40.
Tao X., West A.E., Chen W.G., Corfas G., Greenberg M.E. A calcium-responsive transcription factor, CaRF, that regulates neuronal activity-dependent expression of BDNF. Neuron. 2002;33:383-395.
Not in our library10.1016/s0896-6273(01)00561-x
41.
Zheng F., Wang H. NMDA-mediated and self-induced bdnf exon IV transcriptions are differentially regulated in cultured cortical neurons. Neurochem. Int. 2009;54:385-392.
Not in our library10.1016/j.neuint.2009.01.006
42.
Lipsky R.H., Xu K., Zhu D., Kelly C., Terhakopian A., Novelli A., Marini A.M. Nuclear factor kappaB is a critical determinant in N-methyl-D-aspartate receptor-mediated neuroprotection. J. Neurochem. 2001;78:254-264.
Not in our library10.1046/j.1471-4159.2001.00386.x
43.
Zheng F., Zhou X., Moon C., Wang H. Regulation of brain-derived neurotrophic factor expression in neurons. Int. J. Physiol. Pathophysiol. Pharmacol. 2012;4:188-200.
Not in our library
44.
Jiang X., Tian F., Du Y., Copeland N.G., Jenkins N.A., Tessarollo L., Wu X., Pan H., Hu X.Z., Xu K., et al. BHLHB2 controls Bdnf promoter 4 activity and neuronal excitability. J. Neurosci. 2008;28:1118-1130.
Not in our library10.1523/jneurosci.2262-07.2008
45.
Sakata K., Woo N.H., Martinowich K., Greene J.S., Schloesser R.J., Shen L., Lu B. Critical role of promoter IV-driven BDNF transcription in GABAergic transmission and synaptic plasticity in the prefrontal cortex. Proc. Natl. Acad. Sci. USA. 2009;106:5942-5947.
Not in our library10.1073/pnas.0811431106
46.
Keller S., Sarchiapone M., Zarrilli F., Videtic A., Ferraro A., Carli V., Sacchetti S., Lembo F., Angiolillo A., Jovanovic N., et al. Increased BDNF promoter methylation in the Wernicke area of suicide subjects. Arch. Gen. Psychiatry. 2010;67:258-267.
Not in our library10.1001/archgenpsychiatry.2010.9
47.
Tadić A., Müller-Engling L., Schlicht K.F., Kotsiari A., Dreimüller N., Kleimann A., Bleich S., Lieb K., Frieling H. Methylation of the promoter of brain-derived neurotrophic factor exon IV and antidepressant response in major depression. Mol. Psychiatry. 2014;19:281-283.
Not in our library10.1038/mp.2013.58
48.
Lieb K., Dreimüller N., Wagner S., Schlicht K., Falter T., Neyazi A., Müller-Engling L., Bleich S., Tadić A., Frieling H. BDNF Plasma Levels and BDNF Exon IV Promoter Methylation as Predictors for Antidepressant Treatment Response. Front. Psychiatry. 2018;9:511.
Not in our library10.3389/fpsyt.2018.00511
49.
Sakata K., Duke S.M. Lack of BDNF expression through promoter IV disturbs expression of monoamine genes in the frontal cortex and hippocampus. Neuroscience. 2014;260:265-275.
Not in our library10.1016/j.neuroscience.2013.12.013
50.
Hill J.L., Hardy N.F., Jimenez D.V., Maynard K.R., Kardian A.S., Pollock C.J., Schloesser R.J., Martinowich K. Loss of promoter IV-driven BDNF expression impacts oscillatory activity during sleep, sensory information processing and fear regulation. Transl. Psychiatry. 2016;6:e873.
Not in our library10.1038/tp.2016.153
51.
Volpicelli F., Speranza L., Pulcrano S., De Gregorio R., Crispino M., De Sanctis C., Leopoldo M., Lacivita E., di Porzio U., Bellenchi G.C., et al. The microRNA-29a Modulates Serotonin 5-HT7 Receptor Expression and Its Effects on Hippocampal Neuronal Morphology. Mol. Neurobiol. 2019;56:8617-8627.
Not in our library10.1007/s12035-019-01690-x
52.
De Gregorio R., Pulcrano S., De Sanctis C., Volpicelli F., Guatteo E., von Oerthel L., Latagliata E.C., Esposito R., Piscitelli R.M., Perrone-Capano C., et al. miR-34b/c Regulates Wnt1 and Enhances Mesencephalic Dopaminergic Neuron Differentiation. Stem Cell Rep. 2018;10:1237-1250.
Not in our library10.1016/j.stemcr.2018.02.006
53.
McNeill E., Van Vactor D. MicroRNAs shape the neuronal landscape. Neuron. 2012;75:363-379.
Not in our library10.1016/j.neuron.2012.07.005
54.
Keifer J., Zheng Z., Ambigapathy G. A MicroRNA-BDNF Negative Feedback Signaling Loop in Brain: Implications for Alzheimer′s Disease. Microrna. 2015;4:101-108.
Not in our library10.2174/2211536604666150813152620
55.
Khani-Habibabadi F., Askari S., Zahiri J., Javan M., Behmanesh M. Novel BDNF-regulatory microRNAs in neurodegenerative disorders pathogenesis: An in silico study. Comput. Biol. Chem. 2019;83:107153.
Not in our library10.1016/j.compbiolchem.2019.107153
56.
Schratt G.M., Tuebing F., Nigh E.A., Kane C.G., Sabatini M.E., Kiebler M., Greenberg M.E. A brain-specific microRNA regulates dendritic spine development. Nature. 2006;439:283-289.
Not in our library10.1038/nature04367
57.
Baby N., Alagappan N., Dheen S.T., Sajikumar S. MicroRNA-134-5p inhibition rescues long-term plasticity and synaptic tagging/capture in an Aβ(1-42)-induced model of Alzheimer’s disease. Aging Cell. 2020;19:e13046.
Not in our library10.1111/acel.13046
58.
Gao J., Wang W.Y., Mao Y.W., Gräff J., Guan J.S., Pan L., Mak G., Kim D., Su S.C., Tsai L.H. A novel pathway regulates memory and plasticity via SIRT1 and miR-134. Nature. 2010;466:1105-1109.
Not in our library10.1038/nature09271
59.
Shen J., Xu L., Qu C., Sun H., Zhang J. Resveratrol prevents cognitive deficits induced by chronic unpredictable mild stress: Sirt1/miR-134 signalling pathway regulates CREB/BDNF expression in hippocampus in vivo and in vitro. Behav. Brain Res. 2018;349:1-7.
Not in our library10.1016/j.bbr.2018.04.050
60.
Xin C., Xia J., Liu Y., Zhang Y. MicroRNA-202-3p Targets Brain-Derived Neurotrophic Factor and Is Involved in Depression-Like Behaviors. Neuropsychiatr. Dis. Treat. 2020;16:1073-1083.
Not in our library10.2147/ndt.s241136
61.
Yang C.R., Zhang X.Y., Liu Y., Du J.Y., Liang R., Yu M., Zhang F.Q., Mu X.F., Li F., Zhou L., et al. Antidepressant Drugs Correct the Imbalance Between proBDNF/p75NTR/Sortilin and Mature BDNF/TrkB in the Brain of Mice with Chronic Stress. Neurotox. Res. 2020;37:171-182.
Not in our library10.1007/s12640-019-00101-2
62.
You Y.H., Qin Z.Q., Zhang H.L., Yuan Z.H., Yu X. MicroRNA-153 promotes brain-derived neurotrophic factor and hippocampal neuron proliferation to alleviate autism symptoms through inhibition of JAK-STAT pathway by LEPR. Biosci. Rep. 2019;39.
Not in our library10.1042/bsr20181904
63.
Rostamian Delavar M., Baghi M., Safaeinejad Z., Kiani-Esfahani A., Ghaedi K., Nasr-Esfahani M.H. Differential expression of miR-34a, miR-141, and miR-9 in MPP+-treated differentiated PC12 cells as a model of Parkinson′s disease. Gene. 2018;662:54-65.
Not in our library10.1016/j.gene.2018.04.010
64.
Zhao X., Shu F., Wang X., Wang F., Wu L., Li L., Lv H. Inhibition of microRNA-375 ameliorated ketamine-induced neurotoxicity in human embryonic stem cell derived neurons. Eur. J. Pharmacol. 2019;844:56-64.
Not in our library10.1016/j.ejphar.2018.11.035
65.
Jiang J.D., Zheng X.C., Huang F.Y., Gao F., You M.Z., Zheng T. MicroRNA-107 regulates anesthesia-induced neural injury in embryonic stem cell derived neurons. IUBMB Life. 2019;71:20-27.
Not in our library10.1002/iub.1911
66.
Barde Y.A., Edgar D., Thoenen H. Purification of a new neurotrophic factor from mammalian brain. EMBO J. 1982;1:549-553.
Not in our library10.1002/j.1460-2075.1982.tb01207.x
67.
Foltran R.B., Diaz S.L. BDNF isoforms: A round trip ticket between neurogenesis and serotonin? J. Neurochem. 2016;138:204-221.
Not in our library10.1111/jnc.13658
68.
Mizui T., Ishikawa Y., Kumanogoh H., Kojima M. Neurobiological actions by three distinct subtypes of brain-derived neurotrophic factor: Multi-ligand model of growth factor signaling. Pharmacol. Res. 2016;105:93-98.
Not in our library10.1016/j.phrs.2015.12.019
69.
Lu J., Wu Y., Sousa N., Almeida O.F. SMAD pathway mediation of BDNF and TGF beta 2 regulation of proliferation and differentiation of hippocampal granule neurons. Development. 2005;132:3231-3242.
Not in our library10.1242/dev.01893
70.
BDNF: A Key Factor with Multipotent Impact on Brain Signaling and Synaptic Plasticity · 2017
No notice
71.
Pang P.T., Teng H.K., Zaitsev E., Woo N.T., Sakata K., Zhen S., Teng K.K., Yung W.H., Hempstead B.L., Lu B. Cleavage of proBDNF by tPA/plasmin is essential for long-term hippocampal plasticity. Science. 2004;306:487-491.
Not in our library10.1126/science.1100135
72.
Mizoguchi H., Nakade J., Tachibana M., Ibi D., Someya E., Koike H., Kamei H., Nabeshima T., Itohara S., Takuma K., et al. Matrix metalloproteinase-9 contributes to kindled seizure development in pentylenetetrazole-treated mice by converting pro-BDNF to mature BDNF in the hippocampus. J. Neurosci. 2011;31:12963-12971.
Not in our library10.1523/jneurosci.3118-11.2011
73.
Vafadari B., Salamian A., Kaczmarek L. MMP-9 in translation: From molecule to brain physiology, pathology, and therapy. J. Neurochem. 2016;139(Suppl. S2):91-114.
Not in our library10.1111/jnc.13415
74.
Mowla S.J., Farhadi H.F., Pareek S., Atwal J.K., Morris S.J., Seidah N.G., Murphy R.A. Biosynthesis and post-translational processing of the precursor to brain-derived neurotrophic factor. J. Biol. Chem. 2001;276:12660-12666.
Not in our library10.1074/jbc.m008104200
75.
Conner J.M., Lauterborn J.C., Yan Q., Gall C.M., Varon S. Distribution of brain-derived neurotrophic factor (BDNF) protein and mRNA in the normal adult rat CNS: Evidence for anterograde axonal transport. J. Neurosci. 1997;17:2295-2313.
Not in our library10.1523/jneurosci.17-07-02295.1997
76.
Dieni S., Matsumoto T., Dekkers M., Rauskolb S., Ionescu M.S., Deogracias R., Gundelfinger E.D., Kojima M., Nestel S., Frotscher M., et al. BDNF and its pro-peptide are stored in presynaptic dense core vesicles in brain neurons. J. Cell Biol. 2012;196:775-788.
Not in our library10.1083/jcb.201201038
77.
Yang J., Siao C.J., Nagappan G., Marinic T., Jing D., McGrath K., Chen Z.Y., Mark W., Tessarollo L., Lee F.S., et al. Neuronal release of proBDNF. Nat. Neurosci. 2009;12:113-115.
Not in our library10.1038/nn.2244
78.
Yang J.L., Lin Y.T., Chuang P.C., Bohr V.A., Mattson M.P. BDNF and exercise enhance neuronal DNA repair by stimulating CREB-mediated production of apurinic/apyrimidinic endonuclease 1. Neuromolecular Med. 2014;16:161-174.
Not in our library10.1007/s12017-013-8270-x
79.
Du J., Feng L., Yang F., Lu B. Activity- and Ca(2+)-dependent modulation of surface expression of brain-derived neurotrophic factor receptors in hippocampal neurons. J. Cell Biol. 2000;150:1423-1434.
Not in our library10.1083/jcb.150.6.1423
80.
Meyer-Franke A., Wilkinson G.A., Kruttgen A., Hu M., Munro E., Hanson M.G., Reichardt L.F., Barres B.A. Depolarization and cAMP elevation rapidly recruit TrkB to the plasma membrane of CNS neurons. Neuron. 1998;21:681-693.
Not in our library10.1016/s0896-6273(00)80586-3
81.
Deinhardt K., Chao M.V. Shaping neurons: Long and short range effects of mature and proBDNF signalling upon neuronal structure. Neuropharmacology. 2014;76 Pt C:603-609.
Not in our library10.1016/j.neuropharm.2013.04.054
82.
Anastasia A., Deinhardt K., Chao M.V., Will N.E., Irmady K., Lee F.S., Hempstead B.L., Bracken C. Val66Met polymorphism of BDNF alters prodomain structure to induce neuronal growth cone retraction. Nat. Commun. 2013;4:2490.
Not in our library10.1038/ncomms3490
83.
Teng H.K., Teng K.K., Lee R., Wright S., Tevar S., Almeida R.D., Kermani P., Torkin R., Chen Z.Y., Lee F.S., et al. ProBDNF induces neuronal apoptosis via activation of a receptor complex of p75NTR and sortilin. J. Neurosci. 2005;25:5455-5463.
Not in our library10.1523/jneurosci.5123-04.2005
84.
Roux P.P., Colicos M.A., Barker P.A., Kennedy T.E. p75 neurotrophin receptor expression is induced in apoptotic neurons after seizure. J. Neurosci. 1999;19:6887-6896.
Not in our library10.1523/jneurosci.19-16-06887.1999
85.
Reichardt L.F. Neurotrophin-regulated signalling pathways. Philos. Trans. R. Soc. Lond. B Biol. Sci. 2006;361:1545-1564.
Not in our library10.1098/rstb.2006.1894
86.
Kaplan D.R., Miller F.D. Neurotrophin signal transduction in the nervous system. Curr. Opin. Neurobiol. 2000;10:381-391.
Not in our library10.1016/s0959-4388(00)00092-1
87.
Gonzalez A., Moya-Alvarado G., Gonzalez-Billaut C., Bronfman F.C. Cellular and molecular mechanisms regulating neuronal growth by brain-derived neurotrophic factor. Cytoskeleton (Hoboken). 2016;73:612-628.
Not in our library10.1002/cm.21312
88.
Huang E.J., Reichardt L.F. Trk receptors: Roles in neuronal signal transduction. Annu. Rev. Biochem. 2003;72:609-642.
Not in our library10.1146/annurev.biochem.72.121801.161629
89.
Minichiello L. TrkB signalling pathways in LTP and learning. Nat. Rev. Neurosci. 2009;10:850-860.
Not in our library10.1038/nrn2738
90.
Patel A.V., Krimm R.F. BDNF is required for the survival of differentiated geniculate ganglion neurons. Dev. Biol. 2010;340:419-429.
Not in our library10.1016/j.ydbio.2010.01.024
91.
Chen J., Shehadah A., Pal A., Zacharek A., Cui X., Cui Y., Roberts C., Lu M., Zeitlin A., Hariri R., et al. Neuroprotective effect of human placenta-derived cell treatment of stroke in rats. Cell Transplant. 2013;22:871-879.
Not in our library10.3727/096368911x637380
92.
Wu Y., Wang R., Wang Y., Gao J., Feng L., Yang Z. Distinct Impacts of Fullerene on Cognitive Functions of Dementia vs. Non-dementia Mice. Neurotox. Res. 2019;36:736-745.
Not in our library10.1007/s12640-019-00075-1
93.
Gorski J.A., Zeiler S.R., Tamowski S., Jones K.R. Brain-derived neurotrophic factor is required for the maintenance of cortical dendrites. J. Neurosci. 2003;23:6856-6865.
Not in our library10.1523/jneurosci.23-17-06856.2003
94.
Kwon M., Fernández J.R., Zegarek G.F., Lo S.B., Firestein B.L. BDNF-promoted increases in proximal dendrites occur via CREB-dependent transcriptional regulation of cypin. J. Neurosci. 2011;31:9735-9745.
Not in our library10.1523/jneurosci.6785-10.2011
95.
Orefice L.L., Waterhouse E.G., Partridge J.G., Lalchandani R.R., Vicini S., Xu B. Distinct roles for somatically and dendritically synthesized brain-derived neurotrophic factor in morphogenesis of dendritic spines. J. Neurosci. 2013;33:11618-11632.
Not in our library10.1523/jneurosci.0012-13.2013
96.
BDNF signaling during the lifetime of dendritic spines · 2020
No notice
97.
Yoshii A., Constantine-Paton M. Postsynaptic localization of PSD-95 is regulated by all three pathways downstream of TrkB signaling. Front. Synaptic Neurosci. 2014;6:6.
Not in our library10.3389/fnsyn.2014.00006
98.
More Insight into BDNF against Neurodegeneration: Anti-Apoptosis, Anti-Oxidation, and Suppression of Autophagy · 2017
No notice
99.
Opazo P., Watabe A.M., Grant S.G., O’Dell T.J. Phosphatidylinositol 3-kinase regulates the induction of long-term potentiation through extracellular signal-related kinase-independent mechanisms. J. Neurosci. 2003;23:3679-3688.
Not in our library10.1523/jneurosci.23-09-03679.2003
100.
Leal G., Bramham C.R., Duarte C.B. BDNF and Hippocampal Synaptic Plasticity. Vitam. Horm. 2017;104:153-195.
Not in our library10.1016/bs.vh.2016.10.004
101.
BDNF signaling and survival of striatal neurons · 2014
No notice
102.
Waterhouse E.G., An J.J., Orefice L.L., Baydyuk M., Liao G.Y., Zheng K., Lu B., Xu B. BDNF promotes differentiation and maturation of adult-born neurons through GABAergic transmission. J. Neurosci. 2012;32:14318-14330.
Not in our library10.1523/jneurosci.0709-12.2012
103.
Park H., Poo M.M. Neurotrophin regulation of neural circuit development and function. Nat. Rev. Neurosci. 2013;14:7-23.
Not in our library10.1038/nrn3379
104.
Jaworski J., Spangler S., Seeburg D.P., Hoogenraad C.C., Sheng M. Control of dendritic arborization by the phosphoinositide-3’-kinase-Akt-mammalian target of rapamycin pathway. J. Neurosci. 2005;25:11300-11312.
Not in our library10.1523/jneurosci.2270-05.2005
105.
Kumar V., Zhang M.X., Swank M.W., Kunz J., Wu G.Y. Regulation of dendritic morphogenesis by Ras-PI3K-Akt-mTOR and Ras-MAPK signaling pathways. J. Neurosci. 2005;25:11288-11299.
Not in our library10.1523/jneurosci.2284-05.2005
106.
Finkbeiner S., Tavazoie S.F., Maloratsky A., Jacobs K.M., Harris K.M., Greenberg M.E. CREB: A major mediator of neuronal neurotrophin responses. Neuron. 1997;19:1031-1047.
Not in our library10.1016/s0896-6273(00)80395-5
107.
Xing J., Kornhauser J.M., Xia Z., Thiele E.A., Greenberg M.E. Nerve growth factor activates extracellular signal-regulated kinase and p38 mitogen-activated protein kinase pathways to stimulate CREB serine 133 phosphorylation. Mol. Cell. Biol. 1998;18:1946-1955.
Not in our library10.1128/mcb.18.4.1946
108.
Segal M., Kreher U., Greenberger V., Braun K. Is fragile X mental retardation protein involved in activity-induced plasticity of dendritic spines? Brain Res. 2003;972:9-15.
Not in our library10.1016/s0006-8993(03)02410-7
109.
Petryshen T.L., Sabeti P.C., Aldinger K.A., Fry B., Fan J.B., Schaffner S.F., Waggoner S.G., Tahl A.R., Sklar P. Population genetic study of the brain-derived neurotrophic factor (BDNF) gene. Mol. Psychiatry. 2010;15:810-815.
Not in our library10.1038/mp.2009.24
110.
Momose Y., Murata M., Kobayashi K., Tachikawa M., Nakabayashi Y., Kanazawa I., Toda T. Association studies of multiple candidate genes for Parkinson’s disease using single nucleotide polymorphisms. Ann. Neurol. 2002;51:133-136.
Not in our library10.1002/ana.10079
111.
Ventriglia M., Bocchio Chiavetto L., Benussi L., Binetti G., Zanetti O., Riva M.A., Gennarelli M. Association between the BDNF 196 A/G polymorphism and sporadic Alzheimer’s disease. Mol. Psychiatry. 2002;7:136-137.
Not in our library10.1038/sj.mp.4000952
112.
Egan M.F., Kojima M., Callicott J.H., Goldberg T.E., Kolachana B.S., Bertolino A., Zaitsev E., Gold B., Goldman D., Dean M., et al. The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. Cell. 2003;112:257-269.
Not in our library10.1016/s0092-8674(03)00035-7
113.
Chen Z.Y., Patel P.D., Sant G., Meng C.X., Teng K.K., Hempstead B.L., Lee F.S. Variant brain-derived neurotrophic factor (BDNF) (Met66) alters the intracellular trafficking and activity-dependent secretion of wild-type BDNF in neurosecretory cells and cortical neurons. J. Neurosci. 2004;24:4401-4411.
Not in our library10.1523/jneurosci.0348-04.2004
114.
Chiaruttini C., Vicario A., Li Z., Baj G., Braiuca P., Wu Y., Lee F.S., Gardossi L., Baraban J.M., Tongiorgi E. Dendritic trafficking of BDNF mRNA is mediated by translin and blocked by the G196A (Val66Met) mutation. Proc. Natl. Acad. Sci. USA. 2009;106:16481-16486.
Not in our library10.1073/pnas.0902833106
115.
Tsai S.J. Salivary gland low-intensity pulsed ultrasound (LIPUS) stimulation as a potential treatment for various BDNF-implicated neuropsychiatric disorders. Med. Hypotheses. 2020;137:109560.
Not in our library10.1016/j.mehy.2020.109560
116.
Lin C.C., Huang T.L. Brain-derived neurotrophic factor and mental disorders. Biomed. J. 2020;43:134-142.
Not in our library10.1016/j.bj.2020.01.001
117.
Di Lazzaro V., Pellegrino G., Di Pino G., Corbetto M., Ranieri F., Brunelli N., Paolucci M., Bucossi S., Ventriglia M.C., Brown P., et al. Val66Met BDNF gene polymorphism influences human motor cortex plasticity in acute stroke. Brain Stimul. 2015;8:92-96.
Not in our library10.1016/j.brs.2014.08.006
118.
BDNF Val66Met polymorphism is associated with altered activity-dependent modulation of short-interval intracortical inhibition in bilateral M1. · 2018
Not checked
119.
Hashimoto T., Fukui K., Takeuchi H., Yokota S., Kikuchi Y., Tomita H., Taki Y., Kawashima R. Effects of the BDNF Val66Met Polymorphism on Gray Matter Volume in Typically Developing Children and Adolescents. Cereb. Cortex. 2016;26:1795-1803.
Not in our library10.1093/cercor/bhw020
120.
Meng W.D., Sun S.J., Yang J., Chu R.X., Tu W., Liu Q. Elevated Serum Brain-Derived Neurotrophic Factor (BDNF) but not BDNF Gene Val66Met Polymorphism Is Associated with Autism Spectrum Disorders. Mol. Neurobiol. 2017;54:1167-1172.
Not in our library10.1007/s12035-016-9721-9
121.
Montag C., Basten U., Stelzel C., Fiebach C.J., Reuter M. The BDNF Val66Met polymorphism and anxiety: Support for animal knock-in studies from a genetic association study in humans. Psychiatry Res. 2010;179:86-90.
Not in our library10.1016/j.psychres.2008.08.005
122.
Park C.H., Kim J., Namgung E., Lee D.W., Kim G.H., Kim M., Kim N., Kim T.D., Kim S., Lyoo I.K., et al. The BDNF Val66Met Polymorphism Affects the Vulnerability of the Brain Structural Network. Front. Hum. Neurosci. 2017;11:400.
Not in our library10.3389/fnhum.2017.00400
123.
Hariri A.R., Goldberg T.E., Mattay V.S., Kolachana B.S., Callicott J.H., Egan M.F., Weinberger D.R. Brain-derived neurotrophic factor val66met polymorphism affects human memory-related hippocampal activity and predicts memory performance. J. Neurosci. 2003;23:6690-6694.
Not in our library10.1523/jneurosci.23-17-06690.2003
124.
Pezawas L., Verchinski B.A., Mattay V.S., Callicott J.H., Kolachana B.S., Straub R.E., Egan M.F., Meyer-Lindenberg A., Weinberger D.R. The brain-derived neurotrophic factor val66met polymorphism and variation in human cortical morphology. J. Neurosci. 2004;24:10099-10102.
Not in our library10.1523/jneurosci.2680-04.2004
125.
Ho B.C., Milev P., O’Leary D.S., Librant A., Andreasen N.C., Wassink T.H. Cognitive and magnetic resonance imaging brain morphometric correlates of brain-derived neurotrophic factor Val66Met gene polymorphism in patients with schizophrenia and healthy volunteers. Arch. Gen. Psychiatry. 2006;63:731-740.
Not in our library10.1001/archpsyc.63.7.731
126.
Montag C., Weber B., Fliessbach K., Elger C., Reuter M. The BDNF Val66Met polymorphism impacts parahippocampal and amygdala volume in healthy humans: Incremental support for a genetic risk factor for depression. Psychol. Med. 2009;39:1831-1839.
Not in our library10.1017/s0033291709005509
127.
Xia H., Du X., Yin G., Zhang Y., Li X., Cai J., Huang X., Ning Y., Soares J.C., Wu F., et al. Effects of smoking on cognition and BDNF levels in a male Chinese population: Relationship with BDNF Val66Met polymorphism. Sci. Rep. 2019;9:217.
Not in our library10.1038/s41598-018-36419-8
128.
Altmann V., Schumacher-Schuh A.F., Rieck M., Callegari-Jacques S.M., Rieder C.R., Hutz M.H. Val66Met BDNF polymorphism is associated with Parkinson’s disease cognitive impairment. Neurosci. Lett. 2016;615:88-91.
Not in our library10.1016/j.neulet.2016.01.030
129.
Wang Q., Liu J., Guo Y., Dong G., Zou W., Chen Z. Association between BDNF G196A (Val66Met) polymorphism and cognitive impairment in patients with Parkinson’s disease: A meta-analysis. Braz. J. Med. Biol. Res. 2019;52:e8443.
Not in our library10.1590/1414-431x20198443
130.
Franzmeier N., Ren J., Damm A., Monté-Rubio G., Boada M., Ruiz A., Ramirez A., Jessen F., Düzel E., Rodríguez Gómez O., et al. The BDNF. Mol. Psychiatry. 2019.
Not in our library10.1038/s41380-019-0404-6
131.
Yin Y., Su X., Pan L., Li C. BDNF Val66Met polymorphism and cognitive impairment in Parkinson’s disease-a meta-analysis. Neurol. Sci. 2019;40:1901-1907.
Not in our library10.1007/s10072-019-03907-2
132.
Dalby R.B., Elfving B., Poulsen P.H., Foldager L., Frandsen J., Videbech P., Rosenberg R. Plasma brain-derived neurotrophic factor and prefrontal white matter integrity in late-onset depression and normal aging. Acta Psychiatr. Scand. 2013;128:387-396.
Not in our library10.1111/acps.12085
133.
Choi S., Han K.M., Won E., Yoon B.J., Lee M.S., Ham B.J. Association of brain-derived neurotrophic factor DNA methylation and reduced white matter integrity in the anterior corona radiata in major depression. J. Affect. Disord. 2015;172:74-80.
Not in our library10.1016/j.jad.2014.09.042
134.
Youssef M.M., Underwood M.D., Huang Y.Y., Hsiung S.C., Liu Y., Simpson N.R., Bakalian M.J., Rosoklija G.B., Dwork A.J., Arango V., et al. Association of BDNF Val66Met Polymorphism and Brain BDNF Levels with Major Depression and Suicide. Int. J. Neuropsychopharmacol. 2018;21:528-538.
Not in our library10.1093/ijnp/pyy008
135.
Caldieraro M.A., McKee M., Leistner-Segal S., Vares E.A., Kubaski F., Spanemberg L., Brusius-Facchin A.C., Fleck M.P., Mischoulon D. Val66Met polymorphism association with serum BDNF and inflammatory biomarkers in major depression. World J. Biol. Psychiatry. 2018;19:402-409.
Not in our library10.1080/15622975.2017.1347713
136.
Rong C., Park C., Rosenblat J.D., Subramaniapillai M., Zuckerman H., Fus D., Lee Y.L., Pan Z., Brietzke E., Mansur R.B., et al. Predictors of Response to Ketamine in Treatment Resistant Major Depressive Disorder and Bipolar Disorder. Int. J. Environ. Res. Public Health. 2018;15:771.
Not in our library10.3390/ijerph15040771
137.
Mandolini G.M., Lazzaretti M., Pigoni A., Delvecchio G., Soares J.C., Brambilla P. The impact of BDNF Val66Met polymorphism on cognition in Bipolar Disorder: A review: Special Section on ″Translational and Neuroscience Studies in Affective Disorders″Section Editor, Maria Nobile MD, PhD. This Section of JAD focuses on the relevance of translational and neuroscience studies in providing a better understanding of the neural basis of affective disorders. The main aim is to briefly summaries relevant research findings in clinical neuroscience with particular regards to specific innovative topics in mood and anxiety disorders. J. Affect. Disord. 2019;243:552-558.
Not in our library10.1016/j.jad.2018.07.054
138.
Chen N.C., Chuang Y.C., Huang C.W., Lui C.C., Lee C.C., Hsu S.W., Lin P.H., Lu Y.T., Chang Y.T., Hsu C.W., et al. Interictal serum brain-derived neurotrophic factor level reflects white matter integrity, epilepsy severity, and cognitive dysfunction in chronic temporal lobe epilepsy. Epilepsy Behav. 2016;59:147-154.
Not in our library10.1016/j.yebeh.2016.02.029
139.
Sidhu M.K., Thompson P.J., Wandschneider B., Foulkes A., de Tisi J., Stretton J., Perona M., Thom M., Bonelli S.B., Burdett J., et al. The impact of brain-derived neurotrophic factor Val66Met polymorphism on cognition and functional brain networks in patients with intractable partial epilepsy. CNS Neurosci. Ther. 2019;25:223-232.
Not in our library10.1111/cns.13003
140.
Doherty C., Hogue O., Floden D.P., Altemus J.B., Najm I.M., Eng C., Busch R.M. BDNF and COMT, but not APOE, alleles are associated with psychiatric symptoms in refractory epilepsy. Epilepsy Behav. 2019;94:131-136.
Not in our library10.1016/j.yebeh.2019.02.032
141.
Kheirollahi M., Kazemi E., Ashouri S. Brain-Derived Neurotrophic Factor Gene Val66Met Polymorphism and Risk of Schizophrenia: A Meta-analysis of Case-Control Studies. Cell. Mol. Neurobiol. 2016;36:1-10.
Not in our library10.1007/s10571-015-0229-z
142.
Xia H., Zhang G., Du X., Zhang Y., Yin G., Dai J., He M.X., Soares J.C., Li X., Zhang X.Y. Suicide attempt, clinical correlates, and BDNF Val66Met polymorphism in chronic patients with schizophrenia. Neuropsychology. 2018;32:199-205.
Not in our library10.1037/neu0000383
143.
Huang E., Hettige N.C., Zai G., Tomasi J., Huang J., Zai C.C., Pivac N., Nikolac Perkovic M., Tiwari A.K., Kennedy J.L. BDNF Val66Met polymorphism and clinical response to antipsychotic treatment in schizophrenia and schizoaffective disorder patients: A meta-analysis. Pharmacogenomics J. 2019;19:269-276.
Not in our library10.1038/s41397-018-0041-5
144.
Han M., Deng C. BDNF as a pharmacogenetic target for antipsychotic treatment of schizophrenia. Neurosci. Lett. 2020;726:133870.
Not in our library10.1016/j.neulet.2018.10.015
145.
Brown A., Machan J.T., Hayes L., Zervas M. Molecular organization and timing of Wnt1 expression define cohorts of midbrain dopamine neuron progenitors in vivo. J. Comp. Neurol. 2011;519:2978-3000.
Not in our library10.1002/cne.22710
146.
Ramos-Cejudo J., Gutiérrez-Fernández M., Otero-Ortega L., Rodríguez-Frutos B., Fuentes B., Vallejo-Cremades M.T., Hernanz T.N., Cerdán S., Díez-Tejedor E. Brain-derived neurotrophic factor administration mediated oligodendrocyte differentiation and myelin formation in subcortical ischemic stroke. Stroke. 2015;46:221-228.
Not in our library10.1161/strokeaha.114.006692
147.
Balkaya M., Cho S. Genetics of stroke recovery: BDNF val66met polymorphism in stroke recovery and its interaction with aging. Neurobiol. Dis. 2019;126:36-46.
Not in our library10.1016/j.nbd.2018.08.009
148.
Lohia R., Salari R., Brannigan G. Sequence specificity despite intrinsic disorder: How a disease-associated Val/Met polymorphism rearranges tertiary interactions in a long disordered protein. PLoS Comput. Biol. 2019;15:e1007390.
Not in our library10.1371/journal.pcbi.1007390
149.
Rock P.L., Roiser J.P., Riedel W.J., Blackwell A.D. Cognitive impairment in depression: A systematic review and meta-analysis. Psychol. Med. 2014;44:2029-2040.
Not in our library10.1017/s0033291713002535
150.
Severino V., Farina A., Colucci-D’Amato L., Reccia M.G., Volpicelli F., Parente A., Chambery A. Secretome profiling of differentiated neural mes-c-myc A1 cell line endowed with stem cell properties. Biochim. Biophys. Acta. 2013;1834:2385-2395.
Not in our library10.1016/j.bbapap.2012.12.005
151.
Colucci-D’Amato L., Farina A., Vissers J.P., Chambery A. Quantitative neuroproteomics: Classical and novel tools for studying neural differentiation and function. Stem Cell Rev. Rep. 2011;7:77-93.
Not in our library10.1007/s12015-010-9136-3
152.
Di Lieto A., Leo D., Volpicelli F., di Porzio U., Colucci-D’Amato L. FLUOXETINE modifies the expression of serotonergic markers in a differentiation-dependent fashion in the mesencephalic neural cell line A1 mes c-myc. Brain Res. 2007;1143:1-10.
Not in our library10.1016/j.brainres.2007.01.076
153.
Nawa Y., Kaneko H., Oda M., Tsubonoya M., Hiroi T., Gentile M.T., Colucci-D’Amato L., Takahashi R., Matsui H. Functional characterization of the neuron-restrictive silencer element in the human tryptophan hydroxylase 2 gene expression. J. Neurochem. 2017;142:827-840.
Not in our library10.1111/jnc.14060
154.
Gentile M.T., Nawa Y., Lunardi G., Florio T., Matsui H., Colucci-D’Amato L. Tryptophan hydroxylase 2 (TPH2) in a neuronal cell line: Modulation by cell differentiation and NRSF/rest activity. J. Neurochem. 2012;123:963-970.
Not in our library10.1111/jnc.12004
155.
Duman R.S., Heninger G.R., Nestler E.J. A molecular and cellular theory of depression. Arch. Gen. Psychiatry. 1997;54:597-606.
Not in our library10.1001/archpsyc.1997.01830190015002
156.
Colucci-D’Amato L., di Porzio U. Neurogenesis in adult CNS: From denial to opportunities and challenges for therapy. Bioessays. 2008;30:135-145.
Not in our library10.1002/bies.20703
157.
Colucci-D’Amato L., Bonavita V., di Porzio U. The end of the central dogma of neurobiology: Stem cells and neurogenesis in adult CNS. Neurol. Sci. 2006;27:266-270.
Not in our library10.1007/s10072-006-0682-z
158.
Cramer S.C., Sur M., Dobkin B.H., O’Brien C., Sanger T.D., Trojanowski J.Q., Rumsey J.M., Hicks R., Cameron J., Chen D., et al. Harnessing neuroplasticity for clinical applications. Brain. 2011;134:1591-1609.
Not in our library10.1093/brain/awr039
159.
Castrén E. Neuronal network plasticity and recovery from depression. JAMA Psychiatry. 2013;70:983-989.
Not in our library10.1001/jamapsychiatry.2013.1
160.
Snapyan M., Lemasson M., Brill M.S., Blais M., Massouh M., Ninkovic J., Gravel C., Berthod F., Götz M., Barker P.A., et al. Vasculature guides migrating neuronal precursors in the adult mammalian forebrain via brain-derived neurotrophic factor signaling. J. Neurosci. 2009;29:4172-4188.
Not in our library10.1523/jneurosci.4956-08.2009
161.
Bergami M., Rimondini R., Santi S., Blum R., Götz M., Canossa M. Deletion of TrkB in adult progenitors alters newborn neuron integration into hippocampal circuits and increases anxiety-like behavior. Proc. Natl. Acad. Sci. USA. 2008;105:15570-15575.
Not in our library10.1073/pnas.0803702105
162.
Chan K.L., Tong K.Y., Yip S.P. Relationship of serum brain-derived neurotrophic factor (BDNF) and health-related lifestyle in healthy human subjects. Neurosci. Lett. 2008;447:124-128.
Not in our library10.1016/j.neulet.2008.10.013
163.
Zafra F., Lindholm D., Castrén E., Hartikka J., Thoenen H. Regulation of brain-derived neurotrophic factor and nerve growth factor mRNA in primary cultures of hippocampal neurons and astrocytes. J. Neurosci. 1992;12:4793-4799.
Not in our library10.1523/jneurosci.12-12-04793.1992
164.
Castrén E., Antila H. Neuronal plasticity and neurotrophic factors in drug responses. Mol. Psychiatry. 2017;22:1085-1095.
Not in our library10.1038/mp.2017.61
165.
Castrén E., Zafra F., Thoenen H., Lindholm D. Light regulates expression of brain-derived neurotrophic factor mRNA in rat visual cortex. Proc. Natl. Acad. Sci. USA. 1992;89:9444-9448.
Not in our library10.1073/pnas.89.20.9444
166.
Gianfranceschi L., Siciliano R., Walls J., Morales B., Kirkwood A., Huang Z.J., Tonegawa S., Maffei L. Visual cortex is rescued from the effects of dark rearing by overexpression of BDNF. Proc. Natl. Acad. Sci. USA. 2003;100:12486-12491.
Not in our library10.1073/pnas.1934836100
167.
Hensch T.K., Bilimoria P.M. Re-opening Windows: Manipulating Critical Periods for Brain Development. Cerebrum. 2012;2012:11.
Not in our library
168.
Hong E.J., McCord A.E., Greenberg M.E. A biological function for the neuronal activity-dependent component of Bdnf transcription in the development of cortical inhibition. Neuron. 2008;60:610-624.
Not in our library10.1016/j.neuron.2008.09.024
169.
Volpicelli F., Speranza L., di Porzio U., Crispino M., Perrone-Capano C. The serotonin receptor 7 and the structural plasticity of brain circuits. Front. Behav. Neurosci. 2014;8:318.
Not in our library10.3389/fnbeh.2014.00318
170.
Cazorla M., Arrang J.M., Prémont J. Pharmacological characterization of six trkB antibodies reveals a novel class of functional agents for the study of the BDNF receptor. Br. J. Pharmacol. 2011;162:947-960.
Not in our library10.1111/j.1476-5381.2010.01094.x
171.
Park S.W., Nhu l.H., Cho H.Y., Seo M.K., Lee C.H., Ly N.N., Choi C.M., Lee B.J., Kim G.M., Seol W., et al. p11 mediates the BDNF-protective effects in dendritic outgrowth and spine formation in B27-deprived primary hippocampal cells. J. Affect. Disord. 2016;196:1-10.
Not in our library10.1016/j.jad.2016.02.010
172.
Katoh-Semba R., Asano T., Ueda H., Morishita R., Takeuchi I.K., Inaguma Y., Kato K. Riluzole enhances expression of brain-derived neurotrophic factor with consequent proliferation of granule precursor cells in the rat hippocampus. FASEB J. 2002;16:1328-1330.
Not in our library10.1096/fj.02-0143fje
173.
Cavanaugh J.E., Ham J., Hetman M., Poser S., Yan C., Xia Z. Differential regulation of mitogen-activated protein kinases ERK1/2 and ERK5 by neurotrophins, neuronal activity, and cAMP in neurons. J. Neurosci. 2001;21:434-443.
Not in our library10.1523/jneurosci.21-02-00434.2001
174.
Lin E., Cavanaugh J.E., Leak R.K., Perez R.G., Zigmond M.J. Rapid activation of ERK by 6-hydroxydopamine promotes survival of dopaminergic cells. J. Neurosci. Res. 2008;86:108-117.
Not in our library10.1002/jnr.21478
175.
BDNF impact on synaptic dynamics: extra or intracellular long-term release differently regulates cultured hippocampal synapses · 2020
Not checked
176.
Ernfors P., Lee K.F., Jaenisch R. Mice lacking brain-derived neurotrophic factor develop with sensory deficits. Nature. 1994;368:147-150.
Not in our library10.1038/368147a0
177.
Gao X., Smith G.M., Chen J. Impaired dendritic development and synaptic formation of postnatal-born dentate gyrus granular neurons in the absence of brain-derived neurotrophic factor signaling. Exp. Neurol. 2009;215:178-190.
Not in our library10.1016/j.expneurol.2008.10.009
178.
Mariga A., Zavadil J., Ginsberg S.D., Chao M.V. Withdrawal of BDNF from hippocampal cultures leads to changes in genes involved in synaptic function. Dev. Neurobiol. 2015;75:173-192.
Not in our library10.1002/dneu.22216
179.
Aarse J., Herlitze S., Manahan-Vaughan D. The requirement of BDNF for hippocampal synaptic plasticity is experience-dependent. Hippocampus. 2016;26:739-751.
Not in our library10.1002/hipo.22555
180.
Magariños A.M., Li C.J., Gal Toth J., Bath K.G., Jing D., Lee F.S., McEwen B.S. Effect of brain-derived neurotrophic factor haploinsufficiency on stress-induced remodeling of hippocampal neurons. Hippocampus. 2011;21:253-264.
Not in our library10.1002/hipo.20744
181.
von Bohlen Und Halbach O., von Bohlen Und Halbach V. BDNF effects on dendritic spine morphology and hippocampal function. Cell Tissue Res. 2018;373:729-741.
Not in our library10.1007/s00441-017-2782-x
182.
von Bohlen und Halbach O., Minichiello L., Unsicker K. TrkB but not trkC receptors are necessary for postnatal maintenance of hippocampal spines. Neurobiol. Aging. 2008;29:1247-1255.
Not in our library10.1016/j.neurobiolaging.2007.02.028
183.
Dokter M., Busch R., Poser R., Vogt M.A., von Bohlen Und Halbach V., Gass P., Unsicker K., von Bohlen Und Halbach O. Implications of p75NTR for dentate gyrus morphology and hippocampus-related behavior revisited. Brain Struct. Funct. 2015;220:1449-1462.
Not in our library10.1007/s00429-014-0737-5
184.
Lin P.Y., Kavalali E.T., Monteggia L.M. Genetic Dissection of Presynaptic and Postsynaptic BDNF-TrkB Signaling in Synaptic Efficacy of CA3-CA1 Synapses. Cell Rep. 2018;24:1550-1561.
Not in our library10.1016/j.celrep.2018.07.020
185.
Eyman M., Cefaliello C., Mandile P., Piscopo S., Crispino M., Giuditta A. Training old rats selectively modulates synaptosomal protein synthesis. J. Neurosci. Res. 2013;91:20-29.
Not in our library10.1002/jnr.23133
186.
Nikoletopoulou V., Sidiropoulou K., Kallergi E., Dalezios Y., Tavernarakis N. Modulation of Autophagy by BDNF Underlies Synaptic Plasticity. Cell Metab. 2017;26:230-242.
Not in our library10.1016/j.cmet.2017.06.005
187.
Fujimura H., Altar C.A., Chen R., Nakamura T., Nakahashi T., Kambayashi J., Sun B., Tandon N.N. Brain-derived neurotrophic factor is stored in human platelets and released by agonist stimulation. Thromb. Haemost. 2002;87:728-734.
Not in our library10.1055/s-0037-1613072
188.
Klein A.B., Williamson R., Santini M.A., Clemmensen C., Ettrup A., Rios M., Knudsen G.M., Aznar S. Blood BDNF concentrations reflect brain-tissue BDNF levels across species. Int. J. Neuropsychopharmacol. 2011;14:347-353.
Not in our library10.1017/s1461145710000738
189.
Mondal A.C., Fatima M. Direct and indirect evidences of BDNF and NGF as key modulators in depression: Role of antidepressants treatment. Int. J. Neurosci. 2019;129:283-296.
Not in our library10.1080/00207454.2018.1527328
190.
Molendijk M.L., Spinhoven P., Polak M., Bus B.A., Penninx B.W., Elzinga B.M. Serum BDNF concentrations as peripheral manifestations of depression: Evidence from a systematic review and meta-analyses on 179 associations (N=9484). Mol. Psychiatry. 2014;19:791-800.
Not in our library10.1038/mp.2013.105
191.
Polyakova M., Stuke K., Schuemberg K., Mueller K., Schoenknecht P., Schroeter M.L. BDNF as a biomarker for successful treatment of mood disorders: A systematic & quantitative meta-analysis. J. Affect. Disord. 2015;174:432-440.
Not in our library10.1016/j.jad.2014.11.044
192.
Brain-Derived Neurotrophic Factor and Major Depressive Disorder: Evidence from Meta-Analyses · 2018
No notice
193.
Serra-Millàs M. Are the changes in the peripheral brain-derived neurotrophic factor levels due to platelet activation? World J. Psychiatry. 2016;6:84-101.
Not in our library10.5498/wjp.v6.i1.84
194.
Allen A.P., Naughton M., Dowling J., Walsh A., Ismail F., Shorten G., Scott L., McLoughlin D.M., Cryan J.F., Dinan T.G., et al. Serum BDNF as a peripheral biomarker of treatment-resistant depression and the rapid antidepressant response: A comparison of ketamine and ECT. J. Affect. Disord. 2015;186:306-311.
Not in our library10.1016/j.jad.2015.06.033
195.
Lee B.H., Kim Y.K. Reduced platelet BDNF level in patients with major depression. Prog. Neuropsychopharmacol. Biol. Psychiatry. 2009;33:849-853.
Not in our library10.1016/j.pnpbp.2009.04.002
196.
Pandey G.N., Dwivedi Y., Rizavi H.S., Ren X., Zhang H., Pavuluri M.N. Brain-derived neurotrophic factor gene and protein expression in pediatric and adult depressed subjects. Prog. Neuropsychopharmacol. Biol. Psychiatry. 2010;34:645-651.
Not in our library10.1016/j.pnpbp.2010.03.003
197.
Serra-Millàs M., López-Vílchez I., Navarro V., Galán A.M., Escolar G., Penadés R., Catalán R., Fañanás L., Arias B., Gastó C. Changes in plasma and platelet BDNF levels induced by S-citalopram in major depression. Psychopharmacology. 2011;216:1-8.
Not in our library10.1007/s00213-011-2180-0
198.
Dwivedi Y. The Neurobiological Basis of Suicide. 2012.
Not in our library
199.
Pandey G.N., Ren X., Rizavi H.S., Conley R.R., Roberts R.C., Dwivedi Y. Brain-derived neurotrophic factor and tyrosine kinase B receptor signalling in post-mortem brain of teenage suicide victims. Int. J. Neuropsychopharmacol. 2008;11:1047-1061.
Not in our library10.1017/s1461145708009000
200.
Interaction between stress and the BDNFVal66Met polymorphism in depression: a systematic review and meta-analysis · 2014
No notice
201.
Li M., Du W., Shao F., Wang W. Cognitive dysfunction and epigenetic alterations of the BDNF gene are induced by social isolation during early adolescence. Behav. Brain Res. 2016;313:177-183.
Not in our library10.1016/j.bbr.2016.07.025
202.
Yan T., Wang L., Kuang W., Xu J., Li S., Chen J., Yang Y. Brain-derived neurotrophic factor Val66Met polymorphism association with antidepressant efficacy: A systematic review and meta-analysis. Asia Pac. Psychiatry. 2014;6:241-251.
Not in our library10.1111/appy.12148
203.
Castrén E., Rantamäki T. The role of BDNF and its receptors in depression and antidepressant drug action: Reactivation of developmental plasticity. Dev. Neurobiol. 2010;70:289-297.
Not in our library10.1002/dneu.20758
204.
Crispino M., Volpicelli F., Perrone-Capano C. Role of the Serotonin Receptor 7 in Brain Plasticity: From Development to Disease. Int. J. Mol. Sci. 2020;21:505.
Not in our library10.3390/ijms21020505
205.
Alenina N., Klempin F. The role of serotonin in adult hippocampal neurogenesis. Behav. Brain Res. 2015;277:49-57.
Not in our library10.1016/j.bbr.2014.07.038
206.
Malberg J.E., Eisch A.J., Nestler E.J., Duman R.S. Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus. J. Neurosci. 2000;20:9104-9110.
Not in our library10.1523/jneurosci.20-24-09104.2000
207.
Santarelli L., Saxe M., Gross C., Surget A., Battaglia F., Dulawa S., Weisstaub N., Lee J., Duman R., Arancio O., et al. Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science. 2003;301:805-809.
Not in our library10.1126/science.1083328
208.
Rantamäki T., Castrén E. Targeting TrkB neurotrophin receptor to treat depression. Expert Opin. Ther. Targets. 2008;12:705-715.
Not in our library10.1517/14728222.12.6.705
209.
Speranza L., Labus J., Volpicelli F., Guseva D., Lacivita E., Leopoldo M., Bellenchi G.C., di Porzio U., Bijata M., Perrone-Capano C., et al. Serotonin 5-HT7 receptor increases the density of dendritic spines and facilitates synaptogenesis in forebrain neurons. J. Neurochem. 2017;141:647-661.
Not in our library10.1111/jnc.13962
210.
Speranza L., Giuliano T., Volpicelli F., De Stefano M.E., Lombardi L., Chambery A., Lacivita E., Leopoldo M., Bellenchi G.C., di Porzio U., et al. Activation of 5-HT7 receptor stimulates neurite elongation through mTOR, Cdc42 and actin filaments dynamics. Front. Behav. Neurosci. 2015;9:62.
Not in our library10.3389/fnbeh.2015.00062
211.
Speranza L., Chambery A., Di Domenico M., Crispino M., Severino V., Volpicelli F., Leopoldo M., Bellenchi G.C., di Porzio U., Perrone-Capano C. The serotonin receptor 7 promotes neurite outgrowth via ERK and Cdk5 signaling pathways. Neuropharmacology. 2013;67:155-167.
Not in our library10.1016/j.neuropharm.2012.10.026
212.
Popova N.K., Naumenko V.S. Neuronal and behavioral plasticity: The role of serotonin and BDNF systems tandem. Expert Opin. Ther. Targets. 2019;23:227-239.
Not in our library10.1080/14728222.2019.1572747
213.
Castrén E. Neurotrophins and psychiatric disorders. Handb. Exp. Pharmacol. 2014;220:461-479.
Not in our library10.1007/978-3-642-45106-5_17
214.
Castrén E., Kojima M. Brain-derived neurotrophic factor in mood disorders and antidepressant treatments. Neurobiol. Dis. 2017;97:119-126.
Not in our library10.1016/j.nbd.2016.07.010
215.
Castrén E., Rantamäki T. Role of brain-derived neurotrophic factor in the aetiology of depression: Implications for pharmacological treatment. CNS Drugs. 2010;24:1-7.
Not in our library10.2165/11530010-000000000-00000
216.
Lepack A.E., Fuchikami M., Dwyer J.M., Banasr M., Duman R.S. BDNF release is required for the behavioral actions of ketamine. Int. J. Neuropsychopharmacol. 2014;18.
Not in our library10.1093/ijnp/pyu033
217.
Abdallah C.G., Sanacora G., Duman R.S., Krystal J.H. Ketamine and rapid-acting antidepressants: A window into a new neurobiology for mood disorder therapeutics. Annu. Rev. Med. 2015;66:509-523.
Not in our library10.1146/annurev-med-053013-062946
218.
Monteggia L.M., Zarate C. Antidepressant actions of ketamine: From molecular mechanisms to clinical practice. Curr. Opin. Neurobiol. 2015;30:139-143.
Not in our library10.1016/j.conb.2014.12.004
219.
Björkholm C., Monteggia L.M. BDNF-a key transducer of antidepressant effects. Neuropharmacology. 2016;102:72-79.
Not in our library10.1016/j.neuropharm.2015.10.034
220.
Hoshaw B.A., Malberg J.E., Lucki I. Central administration of IGF-I and BDNF leads to long-lasting antidepressant-like effects. Brain Res. 2005;1037:204-208.
Not in our library10.1016/j.brainres.2005.01.007
221.
Eisch A.J., Bolaños C.A., de Wit J., Simonak R.D., Pudiak C.M., Barrot M., Verhaagen J., Nestler E.J. Brain-derived neurotrophic factor in the ventral midbrain-nucleus accumbens pathway: A role in depression. Biol. Psychiatry. 2003;54:994-1005.
Not in our library10.1016/j.biopsych.2003.08.003
222.
Monteggia L.M., Luikart B., Barrot M., Theobold D., Malkovska I., Nef S., Parada L.F., Nestler E.J. Brain-derived neurotrophic factor conditional knockouts show gender differences in depression-related behaviors. Biol. Psychiatry. 2007;61:187-197.
Not in our library10.1016/j.biopsych.2006.03.021
223.
Monteggia L.M., Barrot M., Powell C.M., Berton O., Galanis V., Gemelli T., Meuth S., Nagy A., Greene R.W., Nestler E.J. Essential role of brain-derived neurotrophic factor in adult hippocampal function. Proc. Natl. Acad. Sci. USA. 2004;101:10827-10832.
Not in our library10.1073/pnas.0402141101
224.
Saarelainen T., Hendolin P., Lucas G., Koponen E., Sairanen M., MacDonald E., Agerman K., Haapasalo A., Nawa H., Aloyz R., et al. Activation of the TrkB neurotrophin receptor is induced by antidepressant drugs and is required for antidepressant-induced behavioral effects. J. Neurosci. 2003;23:349-357.
Not in our library10.1523/jneurosci.23-01-00349.2003
225.
Li Y., Luikart B.W., Birnbaum S., Chen J., Kwon C.H., Kernie S.G., Bassel-Duby R., Parada L.F. TrkB regulates hippocampal neurogenesis and governs sensitivity to antidepressive treatment. Neuron. 2008;59:399-412.
Not in our library10.1016/j.neuron.2008.06.023
226.
Liu R.J., Lee F.S., Li X.Y., Bambico F., Duman R.S., Aghajanian G.K. Brain-derived neurotrophic factor Val66Met allele impairs basal and ketamine-stimulated synaptogenesis in prefrontal cortex. Biol. Psychiatry. 2012;71:996-1005.
Not in our library10.1016/j.biopsych.2011.09.030
227.
Kato T., Fogaça M.V., Deyama S., Li X.Y., Fukumoto K., Duman R.S. BDNF release and signaling are required for the antidepressant actions of GLYX-13. Mol. Psychiatry. 2018;23:2007-2017.
Not in our library10.1038/mp.2017.220
228.
Herring M.P., Puetz T.W., O’Connor P.J., Dishman R.K. Effect of exercise training on depressive symptoms among patients with a chronic illness: A systematic review and meta-analysis of randomized controlled trials. Arch. Intern. Med. 2012;172:101-111.
Not in our library10.1001/archinternmed.2011.696
229.
Ota K.T., Duman R.S. Environmental and pharmacological modulations of cellular plasticity: Role in the pathophysiology and treatment of depression. Neurobiol. Dis. 2013;57:28-37.
Not in our library10.1016/j.nbd.2012.05.022
230.
Schuch F.B., Vancampfort D., Richards J., Rosenbaum S., Ward P.B., Stubbs B. Exercise as a treatment for depression: A meta-analysis adjusting for publication bias. J. Psychiatr. Res. 2016;77:42-51.
Not in our library10.1016/j.jpsychires.2016.02.023
231.
Rasmussen P., Brassard P., Adser H., Pedersen M.V., Leick L., Hart E., Secher N.H., Pedersen B.K., Pilegaard H. Evidence for a release of brain-derived neurotrophic factor from the brain during exercise. Exp. Physiol. 2009;94:1062-1069.
Not in our library10.1113/expphysiol.2009.048512
232.
Seifert T., Brassard P., Wissenberg M., Rasmussen P., Nordby P., Stallknecht B., Adser H., Jakobsen A.H., Pilegaard H., Nielsen H.B., et al. Endurance training enhances BDNF release from the human brain. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2010;298:R372-R377.
Not in our library10.1152/ajpregu.00525.2009
233.
Xu L., Zheng Y.L., Yin X., Xu S.J., Tian D., Zhang C.Y., Wang S., Ma J.Z. Excessive Treadmill Training Enhances Brain-Specific MicroRNA-34a in the Mouse Hippocampus. Front. Mol. Neurosci. 2020;13:7.
Not in our library10.3389/fnmol.2020.00007
234.
de Assis G.G., de Almondes K.M. Exercise-dependent BDNF as a Modulatory Factor for the Executive Processing of Individuals in Course of Cognitive Decline. A Systematic Review. Front. Psychol. 2017;8:584.
Not in our library10.3389/fpsyg.2017.00584
235.
Pajonk F.G., Wobrock T., Gruber O., Scherk H., Berner D., Kaizl I., Kierer A., Müller S., Oest M., Meyer T., et al. Hippocampal plasticity in response to exercise in schizophrenia. Arch. Gen. Psychiatry. 2010;67:133-143.
Not in our library10.1001/archgenpsychiatry.2009.193
236.
Moon H.Y., Becke A., Berron D., Becker B., Sah N., Benoni G., Janke E., Lubejko S.T., Greig N.H., Mattison J.A., et al. Running-Induced Systemic Cathepsin B Secretion Is Associated with Memory Function. Cell Metab. 2016;24:332-340.
Not in our library10.1016/j.cmet.2016.05.025
237.
Boström P., Wu J., Jedrychowski M.P., Korde A., Ye L., Lo J.C., Rasbach K.A., Boström E.A., Choi J.H., Long J.Z., et al. A PGC1-α-dependent myokine that drives brown-fat-like development of white fat and thermogenesis. Nature. 2012;481:463-468.
Not in our library10.1038/nature10777
238.
Wrann C.D., White J.P., Salogiannnis J., Laznik-Bogoslavski D., Wu J., Ma D., Lin J.D., Greenberg M.E., Spiegelman B.M. Exercise induces hippocampal BDNF through a PGC-1α/FNDC5 pathway. Cell Metab. 2013;18:649-659.
Not in our library10.1016/j.cmet.2013.09.008
239.
Lactate and BDNF: Key Mediators of Exercise Induced Neuroplasticity? · 2020
No notice
240.
Piotrowicz Z., Chalimoniuk M., Płoszczyca K., Czuba M., Langfort J. Exercise-Induced Elevated BDNF Level Does Not Prevent Cognitive Impairment Due to Acute Exposure to Moderate Hypoxia in Well-Trained Athletes. Int. J. Mol. Sci. 2020;21:5569.
Not in our library10.3390/ijms21155569
241.
Brain-Derived Neurotrophic Factor: A Key Molecule for Memory in the Healthy and the Pathological Brain · 2019
No notice
242.
Hock C., Heese K., Hulette C., Rosenberg C., Otten U. Region-specific neurotrophin imbalances in Alzheimer disease: Decreased levels of brain-derived neurotrophic factor and increased levels of nerve growth factor in hippocampus and cortical areas. Arch. Neurol. 2000;57:846-851.
Not in our library10.1001/archneur.57.6.846
243.
Zuccato C., Marullo M., Conforti P., MacDonald M.E., Tartari M., Cattaneo E. Systematic assessment of BDNF and its receptor levels in human cortices affected by Huntington′s disease. Brain Pathol. 2008;18:225-238.
Not in our library10.1111/j.1750-3639.2007.00111.x
244.
Narisawa-Saito M., Wakabayashi K., Tsuji S., Takahashi H., Nawa H. Regional specificity of alterations in NGF, BDNF and NT-3 levels in Alzheimer′s disease. Neuroreport. 1996;7:2925-2928.
Not in our library10.1097/00001756-199611250-00024
245.
Hoxha E., Lippiello P., Zurlo F., Balbo I., Santamaria R., Tempia F., Miniaci M.C. The Emerging Role of Altered Cerebellar Synaptic Processing in Alzheimer’s Disease. Front. Aging Neurosci. 2018;10:396.
Not in our library10.3389/fnagi.2018.00396
246.
Peng S., Wuu J., Mufson E.J., Fahnestock M. Precursor form of brain-derived neurotrophic factor and mature brain-derived neurotrophic factor are decreased in the pre-clinical stages of Alzheimer’s disease. J. Neurochem. 2005;93:1412-1421.
Not in our library10.1111/j.1471-4159.2005.03135.x
247.
Choi S.H., Bylykbashi E., Chatila Z.K., Lee S.W., Pulli B., Clemenson G.D., Kim E., Rompala A., Oram M.K., Asselin C., et al. Combined adult neurogenesis and BDNF mimic exercise effects on cognition in an Alzheimer’s mouse model. Science. 2018;361.
Not in our library10.1126/science.aan8821
248.
Exercise promotes the expression of brain derived neurotrophic factor (BDNF) through the action of the ketone body β-hydroxybutyrate · 2016
No notice
249.
Colucci-D’Amato L., Perrone-Capano C., di Porzio U. Chronic activation of ERK and neurodegenerative diseases. Bioessays. 2003;25:1085-1095.
Not in our library10.1002/bies.10355
250.
Activation of Ras-ERK Signaling and GSK-3 by Amyloid Precursor Protein and Amyloid Beta Facilitates Neurodegeneration in Alzheimer’s Disease · 2017
No notice
251.
Nizzari M., Barbieri F., Gentile M.T., Passarella D., Caorsi C., Diaspro A., Taglialatela M., Pagano A., Colucci-D’Amato L., Florio T., et al. Amyloid-β protein precursor regulates phosphorylation and cellular compartmentalization of microtubule associated protein tau. J. Alzheimers Dis. 2012;29:211-227.
Not in our library10.3233/jad-2011-101590
252.
Bartolotti N., Segura L., Lazarov O. Diminished CRE-Induced Plasticity is Linked to Memory Deficits in Familial Alzheimer’s Disease Mice. J. Alzheimers Dis. 2016;50:477-489.
Not in our library10.3233/jad-150650
253.
Rosa E., Fahnestock M. CREB expression mediates amyloid β-induced basal BDNF downregulation. Neurobiol. Aging. 2015;36:2406-2413.
Not in our library10.1016/j.neurobiolaging.2015.04.014
254.
Thiele C.J., Li Z., McKee A.E. On Trk--the TrkB signal transduction pathway is an increasingly important target in cancer biology. Clin. Cancer Res. 2009;15:5962-5967.
Not in our library10.1158/1078-0432.ccr-08-0651
255.
Xiong J., Zhou L.I., Lim Y., Yang M., Zhu Y.H., Li Z.W., Fu D.L., Zhou X.F. Mature brain-derived neurotrophic factor and its receptor TrkB are upregulated in human glioma tissues. Oncol. Lett. 2015;10:223-227.
Not in our library10.3892/ol.2015.3181
256.
Colucci-D’Amato G.L., D’Alessio A., Califano D., Cali G., Rizzo C., Nitsch L., Santelli G., de Franciscis V. Abrogation of nerve growth factor-induced terminal differentiation by ret oncogene involves perturbation of nuclear translocation of ERK. J. Biol. Chem. 2000;275:19306-19314.
Not in our library10.1074/jbc.275.25.19306
257.
Radin D.P., Patel P. BDNF: An Oncogene or Tumor Suppressor? Anticancer. Res. 2017;37:3983-3990.
Not in our library10.21873/anticanres.11783
258.
Wang X., Prager B.C., Wu Q., Kim L.J.Y., Gimple R.C., Shi Y., Yang K., Morton A.R., Zhou W., Zhu Z., et al. Reciprocal Signaling between Glioblastoma Stem Cells and Differentiated Tumor Cells Promotes Malignant Progression. Cell Stem Cell. 2018;22:514-528.
Not in our library10.1016/j.stem.2018.03.011
259.
Garofalo S., D’Alessandro G., Chece G., Brau F., Maggi L., Rosa A., Porzia A., Mainiero F., Esposito V., Lauro C., et al. Enriched environment reduces glioma growth through immune and non-immune mechanisms in mice. Nat. Commun. 2015;6:6623.
Not in our library10.1038/ncomms7623
260.
Garofalo S., Porzia A., Mainiero F., Di Angelantonio S., Cortese B., Basilico B., Pagani F., Cignitti G., Chece G., Maggio R., et al. Environmental stimuli shape microglial plasticity in glioma. Elife. 2017;6.
Not in our library10.7554/elife.33415
261.
Ruta graveolens as a potential source of neuroactive compounds to promote and restore neural functions · 2020
Not checked
262.
Gentile M.T., Ciniglia C., Reccia M.G., Volpicelli F., Gatti M., Thellung S., Florio T., Melone M.A., Colucci-D’Amato L. Ruta graveolens L. induces death of glioblastoma cells and neural progenitors, but not of neurons, via ERK 1/2 and AKT activation. PLoS ONE. 2015;10:e0118864.
Not in our library10.1371/journal.pone.0118864

Cited by papers we hold 3

The Potential Health Benefits of Gallic Acid: Therapeutic and Food Applications · 2024
No notice
Neuroinflammation, memory, and depression: new approaches to hippocampal neurogenesis · 2023
No notice
Recent Advances on the Role of Brain-Derived Neurotrophic Factor (BDNF) in Neurodegenerative Diseases · 2022
No notice

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.